

Joseph Costantino

Professor, Biostatistics

Address

201 N Craig Street; Suite 350
PA 15213

Phone

Work: (412) 383-2638

Email

Work: costan@pitt.edu

Experience

Academic Appointments

Director, NRG Oncology Statistics and Data Management Center, NRG Oncology Cooperative Group	2014-present
Director, NSABP Biostatistical Center, NSABP Biostatistical Center	2004-2014
Professor of Biostatistics with Tenure, Department of Biostatistics, University of Pittsburgh, Graduate School of Public Health	2002-present
Associate Professor of Biostatistics with Tenure, Department of Biostatistics, University of Pittsburgh, Graduate School of Public Health	1998-2002
Associate Director, NSABP Biostatistical Center, NSABP Biostatistical Center	1995-2003
Associate Professor of Biostatistics, Department of Biostatistics, University of Pittsburgh, Graduate School of Public Health	1995-1998
Coordinating Statistician, Breast Cancer Prevention Research, NSABP Biostatistical Center	1991-1995
Assistant Professor of Biostatistics, Department of Biostatistics, University of Pittsburgh, Graduate School of Public Health	1985-1995
Director, Beta Carotene Biostatistical Center, Clinical Trial of Beta Carotene and Lung Cancer University of Pittsburgh, Graduate School of Public Health	1984-1989
Project Statistician, NSABP Biostatistical Center	1984-1991
Adjunct Assistant Professor of Biostatistics and Epidemiology, Department of Biostatistics, University of Pittsburgh, Graduate School of Public Health	1983-1985
Adjunct Instructor of Epidemiology, Department of Epidemiology, University of Pittsburgh, Graduate School of Public Health	1977-1983
Instructor of Epidemiology, Department of Epidemiology, University of Pittsburgh, Graduate School of Public Health	1976-1977

Non-Academic Employment

Manager, Environmental and Occupational Health Research, BCR National Laboratory	1982-1984
Supervisor, Health Effects Research, Bituminous Coal Research, Inc	1980-1981
Executive Assistant Director, Allegheny County Health Department	1979-1980
Deputy Director of Medical Services, Allegheny County Health Department	1977-1979
Chief of Epidemiology, Allegheny County Health Department	1977

Education

Degrees

DrPH Epidemiology, University of Pittsburgh, Graduate School of Public Health	1974-1976
MPH Epidemiology, University of Pittsburgh, Graduate School of Public Health	1972-1974
BS Biology, Bethany College	1968-1972

Committee Memberships

University of Pittsburgh Senate Computer Usage Committee	2000-2019
University of Pittsburgh Faculty Assembly	2003-2017
University of Pittsburgh Faculty Senate Council	2003-2017
Search Committee for New Faculty Members in the Department of Biostatistics	2014-2015
Search Committee for Research Assistant Professor Position in the Department of Biostatistics	2012-2013
Search Committee for Two New Tenure-Track Faculty Positions in the Department of Biostatistics	2012-2013
University of Pittsburgh Board of Trustee's Audit Committee	2008-2012
Search Committee for Director of the UPCI Biostatistical Facility	2009
GSPH Junior Faculty Oversight Committee for the Department of Human Genetics, Environmental and Occupational Health, and Infectious Disease and Microbiology	2007-2008
GSPH Search Committee for Director of the Epidemiology Data Center	2006-2007
GSPH Accreditation Committee	2004-2007
GSPH Search Committee for Dean of the Graduate School of Public Health	2005-2006
GSPH Steering Committee for the Center for Public Health Practice	1995-2006
GSPH Faculty Advancement, Promotion, Tenure Committee (Chair)	2001-2005
GSPH Budget Policy and Planning Committee	1999-2005
GSPH Council	1999-2005
GSPH Faculty Senate Executive Committee (President 2001 and 2002)	1999-2005
Department of Biostatistics Budget and Planning Committee	1993-2005
GSPH Search Committee for the Chair of the Department of Epidemiology (Chair)	2002-2003
GSPH Ad Hoc Committee for Retreat Planning	2001-2002
GSPH Search Committee for Director of MMPH Program	2001-2002
GSPH Search Committee for Dean of the Graduate School of Public Health, (Co-chair)	2000-2001
University of Pittsburgh Faculty Senate Council	1996-2001
University of Pittsburgh Faculty Assembly	1995-2001
GSPH Advisory Committee for the Joint MD/MPH Program	1996-2000
GSPH Committee for the Integrated Core Course in Public Health	1995-1997
University of Pittsburgh Council for Graduate Study	1991-1997
University of Pittsburgh Subcommittee on Evaluation of Academic Programs	1991-1997
Doctoral Student Organization	1991-1994
GSPH Alumni Executive Committee	1986-1994
GSPH Accreditation Committee	1993

GSPH Educational Policies and Curriculum Committee	1991-1993
GSPH School-wide Master's of Public Health Committee	1991-1993
Computer Advisory Committee of the Pittsburgh Cancer Institute	1986-1988
Executive Committee of the Department of Biostatistics NIH Shared Computer	1986-1987

Distinctions

Distinguish Alumni, Graduate School of Public Health, University of Pittsburgh	2005
President, Delta Omega, Omicron Chapter	1990
RJ Lee, Environmental Health Training Award	1989
President-Elect, Delta Omega, Omicron Chapter	1989
Delta Omega, Public Health Honor Society	1987

Teaching Activity

Courses taught

Infectious Disease Epidemiology, course code: Epidemiology-2160	2003-2004
Design of Clinical Trials II: Contemporary Issues, course code: Epidemiology-2182	2002-2006
Clinical Trials: Methods and Practice, course code: Biostatistics-2062	2000-2005
Design of Clinical Trials, course code: Epidemiology-2181	2000-2002
Principles of Epidemiology, course code: Epidemiology-2100	1999-2006
Clinical Epidemiology and Biostatistics	1998-2000
Integrative Course in Public Health, course code: Public Health-2001	1996-1998
Statistical Methods in Public Health, course code: Biostatistics-2045	1985-2013
Principles of Statistical Reasoning, course code: Biostatistics-2011	1984-1988
Principles of Epidemiology, course code: Epidemiology-201	1973-1976

Mentoring

Doctoral Student Dissertation Committees

Inference on quantile residual life for length-biased survival data, Sima Lopa	2014-2015
Dynamic prediction in competing risks, Qing Liu	2012-2014
Statistical methods for classification based on dose response data: A modified EM algorithm for regression analysis of missing data, Zhang, Yang	2012-2013
Use of bias coin methodology for randomization in clinical trials, Tu, Li-Chaun (Primary Advisor, Committee Chair)	2011-2013
Survival analysis of shared-path adaptive treatment strategies, Kidwell, Kelly	2010-2012
Issues in Breast Cancer Prevention: Body Mass Index, Breast Density, and Fractures, Cecchini, Reena	2010-2012
A meta-analytic framework for combining incomparable Cox proportional hazard models caused by omitting important covariates, Yuan, Xing	2008-2010
Analyzing survival data from sequentially randomized designs, Tang, Xinyu	2008-2010
Prediction of accrual closure date in multi-center clinical trials with Poisson process models, Kong, Yuan	2007-2009
Association of emergency room visits for asthma with air quality in Allegheny County, Glad, Jo Ann	2007-2009
Inference on competing risk in breast cancer data, Haile, Sarah	2006-2008

Inference on median residual life function for censored survival data, Bandos, Hanna	2005-2007
Estrogen metabolism, breast density and breast cancer, Simpson, Jennifer	2004-2006
Geographic variations in stroke incidence and mortality among older populations in four U.S. communities, El-Saed, Aiman	2004-2006
Study of risk factors for post-operative pulmonary complications, Wojnakowski, Mary	2002-2004
Assessment of the potential ascertainment bias associated with the use of biopsies from non-systematic follow-up of liver transplant patients, Ruppert, Kristine (Primary Advisor, Committee Chair)	2002-2004
Impairment of endothelial function in women with a history of preeclampsia; an indicator of cardiovascular risk, Agatista, Patricia	2001-2003
A Bayesian group sequential approach for multiple endpoints, Mor, Maria Katrina	2001-2003
Methods for combining covariate data obtained by multiple sampling schemes in occupational cohort, Gaus, Christine	1999-2001
The assessment of environmental and socioeconomic factors with respiratory health in Nigerian families, Gathuru, Irene	1999-2001
Determining the prevalence of early male pattern baldness and risk of coronary heart disease in brothers of women with poly-cystic ovary syndrome, Remsberg, Karen	1999-2001
Violent behavior among youth drinkers: pattern and predictors, Swan, Monica	1999-2001
Evaluation of the Erie County immunization registry of children 12 to 23 months of age, Rea, Nancy	1998-2000
Bone mineral density among women with polycystic ovary syndrome, Zbrowski, Jeanne	1998-2000
Utilization of compliance information in clinical trials. A new methodology, Chen, Wei (Primary Advisor, Committee Chair)	1998-2000
Bone mineral density, breast density and sex steroid hormones in older women, Ngo, Duyen L.	1997-1999
An expert system to assess the effect of molecular modification on drug response, Cunningham, Albert	1996-1998
The relationship of psychopathology, psychosocial, family and neurological course of illness factors to relapse in of schizophrenia, Pandalai, Sudha P.	1996-1998
Meta-analysis with sparse data, dichotomized discrete outcomes, and linear regression applied to ordinal data, Sankey, Scott	1996-1998
Women's perceptions of the value of genetic screening at different life stages, Twal, Marie McConville	1996-1998
Homocysteine and leptin levels in African-American women as related to subclinical atherosclerosis, Zeigler-Johnson, Charnita	1996-1998
Comparison of variances estimates of the standard mortality ratio in the presence of small comparison populations, Lieb, Anita	1995-1997
A simulation study of statistical modeling with neural networks, Landsittel, Douglas	1995-1997
The additive hazards model and its application to the analysis of censored data, Lee, Eunyong Choi	1994-1996
Iterative allocation of partially classified data in epidemiologic studies, Youk, Ada Owens	1994-1996
Multiple endpoint problems in survival analysis, Dignam, James	1992-1994
Comparison and evaluation of smoothing methods and their application to toxicological bioassays, Boylstein, Lee Ann	1992-1994
Socio-economic status and John Henryism: Associations with blood Pressure in a Nigerian civil servant Population, Markovic, Nina	1992-1994

The role of thyroid function in weight and cholesterol changes among menopausal women, Massoudi, Mehran	1991-1993
Electrocardiography left ventricular hypertrophy and related factors in Nigerians, Houston, Sara	1991-1993
Evaluation of the D/ART Training Program, McDonald, Margaret	1991-1993
An analysis of nutrient intake, eating behaviors, and risk for coronary heart disease in premenopausal women, Nowalk, May P	1991-1993
Covariates associated with neonatal and post-neonatal mortality: The case of Peru, Valencia, Ramos G	1989-1991
The relationship between risk factors and the mentally ill homeless: predictors of homelessness in the mentally ill, Kim, Min Shik	1989-1991
Procedure for stopping long-term clinical trials via requiring "r" rejections out of "n" multiple looks to control elevation of type I error, Hussein, Mohamed	1988-1990
An epidemiologic study of lipid levels in adult cystic fibrosis patients, Slesinski, Mary Jane	1988-1990
Nutritional status of vegetarians, Ferris, Denise	1987-1989
Master's Student Essay Committees	
Functional and Medical Impairments among hospitalized older-drivers, Agimi, Yll	2011-2012
Inference on median failure time for censored survival data, Tang, Shaowu, (Primary Advisor, Committee Chair)	2009-2010
Is there a difference in completeness of radiation treatment when comparing African American and Caucasian Women?, Glover, Khaleelah	2008-2009
Estimating the probability of Lymphedema following breast cancer surgery, Wenchi, Wu	2007-2008
Syndromic surveillance for the early detection of influenza outbreaks, Rizzo, Sarah (Primary Advisor, Committee Chair)	2004-2005
Psychometric Evaluation of NSABP C-07 Neurotoxicity self-administered Questionnaire, Sundry, Reena (Primary Advisor, Committee Chair)	2003-2004
A method to identify potential longitudinal biomarkers for survival, Ko, Feng-shou (Primary Advisor, Committee Chair)	2003-2004
Prostate cancer, androgen deprivation and the risk of periodontal disease studies, Famili, Pouran	2002-2003
Statistical Properties of Tree-structure models for survival data, Gao, Weimin	2002-2003
Cardiopulmonary manifestations of systemic lupus erythematosus; evaluation and management, Kao, Amy	2002-2003
Factor composition of the Cannon-Spoor Premorbid Adjustment Scale and the Implications of a multidimensional model, Garratt, Lorraine (Primary Advisor, Committee Chair)	1995-1996
Environmental tobacco smoke exposure and illness in young children, Sledak, Suzanne (Primary Advisor, Committee Chair)	1994-1995
The association between pollution and respiratory hospital admissions in Allegheny County, Pennsylvania, Sankey, Scott (Primary Advisor, Committee Chair)	1991-1992
Assessment of factors associated with Rhabdomyosarcoma, Johnson, Elizabeth (Primary Advisor, Committee Chair)	1991-1992
Prediction of mortality from summary electrocardiogram parameters, Cecchetti, Alfred (Primary Advisor, Committee Chair)	1991-1992
An analysis of prognostic indicators of chronic rejection of lung transplants, Similo, Shari (Primary Advisor, Committee Chair)	1991-1992

Giardiasis detection by a commercial elisa, ProSpec T/giardia, Van Praagh, Andrew D.	1991-1992
Assessment of factors associated with rhabdomyosarcoma, DeSensi, Elizabeth	1991-1992
The effect of blood transfusion on disease-free survival and survival of patients with colon cancer, Jones, Judy	1990-1991
Evaluation of microbial resistance through production of beta-lactamase in otitis media pathogens, Kasian, Charlene	1989-1990
Cancer clusters: an approach to study for the occupational physician, Kemp, Margaret	1989-1990
A comparison of survival between black and white female breast cancer patients participating in NSABP randomized clinical trials., Dignam, James	1988-1989
Cause-Specific mortality in non-Allegheny County coke oven workers, Bearden, Audrey (Primary Advisor, Committee Chair)	1988-1989
Methods to control for normal mortality risk in a study with long-term follow-up; comparison of the relative and the adjusted survival rates, Diklah, Ron	1988-1989
A comparative analysis of growth curve modeling in a population of cleft-palate children, Beres, Leslie	1986-1987
Assessing multiple endpoints associated with occupational exposure: a multivariate approach with application to a sample of chemical workers, Lyons, Ella	1985-1986
The Cauchy distribution as an alternative to the normal for certain biomedical measurements, Ubringer, Elizabeth	1984-1985

Graduate Student Researcher Supervision

GSR position in the NSABP SDMC, Zhang, Yang	2012-2014
GSR position in the NSABP SDMC, Liu, Qing	2011-2014
GSR position in the NSABP SDMC, Christian, Nicholas	2010-2012
GSR position in the NSABP SDMC, Kidwell, Kelly	2010-2012
GSR position in the NSABP SDMC, Haile, Sarah	2007-2008
GSR position in the NSABP SDMC, Bandos, Hanna	2004-2007
GSR position in the NSABP SDMC, Dean, Scott	2004-2006
GSR position in the NSABP SDMC, Sundry, Reena	2002-2004

Professional Activity

Consulting / Advisories

NRG Oncology Board of Directors	2014-2019
Olympia Study Scientific Steering Committee, Olympia Study Scientific Steering Committee	2014-2019
National Clinical Trial Network Leadership Committee, National Cancer Institute	2014-2019
National Cancer Institute National Clinical Trials Network Working Group, National Cancer Institute	2012-2014
Federal Drug Administration Panel on Innovations in Breast Cancer Drug Development	2012-2013
American Society of Clinical Oncology Expert Panel on 5-Alpha-Reductase Inhibitors	2010-2012
National Cancer Institute Program for Assessment of Clinical Cancer Tests Clinical Assay Development Program Eligibility Criteria Working Group	2010-2011
National Cancer Institute Clinical Trials Planning Committee: Next generation trials for HER2-positive breast cancer	2010-2011
National Cancer Institute, Breast Cancer Steering Committee, National Cancer Institute	2009-2019

Statistical Task Force of the American Joint Committee on Cancer	2006-2009
Foregut Task Force of the American Joint Committee on Cancer	2006-2009
American Society of Clinical Oncology Expert Panel on 5-Alpha-Reductase Inhibitors	2006-2008
National Cancer Institute's Working Group on the Feasibility of a Physical Activity, Weight Control Trial to Prevent Breast Cancer	2006
Early Breast Cancer Trialist Cooperative Group Scientific Steering Committee	2005-2019
NSABP Foundation Board of Scientific Directors, NSABP Foundation INC	2005-2019
Institute of Medicine's Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy	2002-2003
Review Panel-National Cancer Institute, Small Grants Program for Cancer Epidemiology	2002
Advisory Committee-NIEHS Program Project: Molecular Toxicology of Environmental Carcinogens	1991-1997
Special Review Committee-National Institute of Heart, Lung and Blood, Clinical Coordinating Center for	1990

Grants

National Cancer Institute through subcontract with SWOG (PI), A randomized Phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes, \$969,740	2019-2026
National Cancer Institute through subcontract with University of Chicago (PI-multiple), U10CA180822 NRG Oncology Statistics and Data Management Center, \$60,799,128	2019-2025
NSABP Foundation, Inc (Co-investigator), Colorectal cancer metastatic dMMR immunotherapy (COMMIT) study: A randomized Phase III study of mFOLFOX/Bevacizumab combination chemotherapy with or without atezolizumab in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer, \$1,141,993	2019-2023
NSABP Foundation, Inc. (PI), A randomized double-blind, Phase II clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple-negative breast cancer followed by adjuvant continuation of atezolizumab, \$373,461	2018-2025
GOG Foundation, Inc (PI), PHAR1-NRG-GY008, \$77,965	2018-2023
National Cancer Institute through subcontract with Cedars-Sinai Medical Center (PI), Advance analysis and interpretation of adverse events and PROs in cancer clinical trials, \$172,735	2018-2019
National Cancer Institute through subcontract with Washington University (PI), 5U10CA180860, Intergrated Translational Genoproteomics Center at Washington University, \$58,722	2017-2019
NSABP Foundation Inc. (Co-investigator), Data Management center for ARGO, A phase III randomized placebo-controlled study evaluating regorafenib following completion of standard chemotherapy for patients with stage III colon cancer, \$5,882,891	2016-2024
NSABP Foundation Inc. (PI), Supplement to support the implementation of B-55, a randomized Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with high risk germline BRCA mutated HER2 negative primary breast cancer, \$1,607,837	2014-2027
National Cancer Institute (PI-multiple), 5 U10 CA180822 NRG Oncology Statistical and Data Management Center, \$45,725,137	2014-2019
National Cancer Institute via subcontract with the NRG Oncology Foundation (PI-multiple), 5 UG1 CA189867 NRG Oncology Statistics and Data Management Center-NCORP Research Base, \$13,363,077	2014-2019
NSABP Foundation Inc. (PI), NSABP Foundation Core Support, \$909,091	2014-2019

NSABP Foundation Inc. (PI), Supplemental to support the alliance of the NSABP , RTOG, and GOG into NRG Oncology Group, \$518,744	2011-2013
NSABP Foundation Inc. (PI), GHI Study 5-038, \$22,828	2011-2012
NSABP Foundation Inc. (Co-investigator), Pre-implementation Development for a Phase III Trial to test the value of Bevacizumab Given for Two Years in Combination with 5-FU, Leucovorin, and Oxaliplatin Given for 6 Months in Patients with Stage III Colon Cancer, \$280,000	2010
NSABP Foundation Inc. (Co-investigator), Long-term follow-up of patients in a phase III trial comparing the combination of TC plus bevacizumab to TC alone and to TAC for women with node-positive or high-risk node-negative, HER2-negative breast cancer, \$4,572,935	2009-2021
NSABP Foundation Inc. (PI), A randomized phase III study to evaluate trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with Her-2+ breast cancer who have residual tumor present after preoperative therapy, \$4,810,701	2009-2021
NSABP Foundation Inc. (PI), Phase III trial to compare the safety and efficacy of Adriamycin and Cyclophosphamide Followed by Taxol to that of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin in Node-Positive, HER2+ Breast Cancer Patients, \$124,800	2009-2012
NSABP Foundation Inc. (PI), Phase III trial assessing bevacizumab with trastuzumab adjuvant therapy in HER2+ breast cancer patients (BETH Trial): NSABP B-44-I - Protocol Development, \$1,422,106	2008-2014
NSABP Foundation Inc. (PI), Phase III trial of neoadjuvant therapy for patients with palpable and operable HER2-positive breast cancer comparing the combination of trastuzumab plus lapatinib to trastuzumab and to lapatinib administered with weekly paclitaxel following AC, \$354,000	2007-2014
NSABP Foundation Inc. (PI), NSABP Biostatistical Center Core Support, \$845,454	2006-2009
NSABP Foundation Inc. (PI), NSABP Biostatistical Center Core Support, \$259,091	2005-2006
NSABP Foundation Inc. (PI), NSABP Biostatistical Center Core Support, \$733,000	2003-2006
Discovery International (Co-investigator), Breast cancer risk assessment education for health professionals, \$12,000	1999
National Cancer Institute (PI), 5 U10 CA 069974 CCOP Biostatistical Center, \$32,491,346	1995-2015
National Cancer Institute (PI), 5 U10 CA069651 Biostatistical Center for the NSABP, \$25,562,870	1995-2014
R.J. Lee Group (PI-sole), Environmental Health Training Grant, \$63,390	1989-1992
U.S. Environmental Protection Agency (Co-investigator), Surveillance of Giardia Infections through Analysis of Fecal Samples and Raw Sewage, \$50,000	1989-1991
Allegheny County Health Department (Co-investigator), Feasibility Study of Community Health Effects Associated with Coke Oven Emissions-Part D, \$25,000	1989-1990
Pennsylvania State Department of Environmental Resources (Co-investigator), Feasibility Study of Community Health Effects Associated with Coke Oven Emissions-Part A, \$30,000	1989-1990
USX Corporation (Co-investigator), Feasibility Study of Community Health Effects Associated with Coke Oven Emissions-Part B, \$50,000	1989-1990
Pennsylvania Department of Health (Co-investigator), Statistical Analysis of the Drake Superfund Site Drake Occupational Health Survey, \$16,000	1985
Environmental Protection Agency (Co-investigator), Morbidity Survey of Coke Oven Workers, \$24,200	1984-1985
Environmental Protection Agency (Co-investigator), Cancer Risk Assessment Based on Coke Oven Workers Mortality, \$303,800	1983-1986
Consolidation and Peabody Coal Companies (PI-sole), Assessment of Coal Related Environmental and Occupational Health Risk, \$34,200	1983-1984

Environmental Protection Agency (Co-investigator), Clinical Evaluation of Health Status Among Coke Oven Workers, \$36,300	1983-1984
National Coal Association (PI-sole), Statistical Evaluation of Data from Precipitation Quality Network, \$31,700	1983-1984
American Mining Congress (PI-sole), Assessment of Respirable Particulate Levels at Surface Mining Operations, \$70,000	1982-1983
Kerr McGee Coal Corporation (PI-sole), Assessments of Health Risk Associated with Use of Diesel Equipment in Underground Coal Mines, \$9,700	1982
North American and Old Ben Coal Companies (PI-sole), Analysis of Federal Coal Mine Safety and Health Legislation, \$14,900	1982
Reitz Coal Company (PI-sole), Evaluation of Respirable Dust Levels at a Coal Preparation Plant, \$6,200	1982
National Coal Association (PI-sole), Environmental Health Risk Associated with Mining Preparation and Utilization of Coal, \$140,000	1980-1981

Publications

Books

Blazer, D. G., Barrent-Conner, E., Brody, B. A., Califf, R. M., Costantino, J. P., Federman, D. D., . . . Vaughan, Jr., E. D. (2004). *Testosterone and Aging: Clinical Research Directions*. C. T. Liverman, & D. G. Blazer (Eds.), Washington D.C.: The National Academies Press.

Chapters

- Costantino, J. P. (2008). Benefit/risk assessment in prevention trials. In R. D'Agostino, L. M. Sullivan, & J. Marssaro (Eds.), *Wiley Encyclopedia of Clinical Trials* (pp. 1-8). John Wiley and Sons.
- Redmond, C. K., Costantino, J. P., & Colton, T. (2006). Challenges in monitoring the Breast Cancer Prevention Trial. In *Data Monitoring in Clinical Trials: A Case Studies Approach* (pp. 118-135). doi:[10.1007/0-387-30107-0_11](https://doi.org/10.1007/0-387-30107-0_11)
- Wickerham, D. L., & Costantino, J. P. (2003). Tamoxifen for chemoprevention. In M. Morrow, & C. V. Jordon (Eds.), *Managing Breast Cancer Risk* (pp. 175-185). Hamilton, Ontario: BC Decker, Inc..
- Wickerham, D. L., & Costantino, J. P. (2003). Breast cancer prevention: the U.S.A. point of view. In *Breast Cancer Management: Application of evidence to Patient Care* (2nd ed., pp. 535-547). Philadelphia, PA: Lippincott, Williams and Wilkins.
- Costantino, J. P. (2001). Benefit/risk assessment. In C. K. Redmond, & T. Colton (Eds.), *Biostatistics in Clinical Trials* (pp. 18-25). Wiley.
- Costantino, J. P. (1999). Evaluating women for breast cancer risk reduction therapy. In *American Society of Clinical Oncology Fall Education Book* (pp. 208-214). American Society of Clinical Oncology.

Journal articles

- Gray, R., Bradley, R., Braybrooke, J., Liu, Z., Peto, R., Davies, L., . . . Jackisch, C. (2019). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. *The Lancet*, 393(10179), 1440-1452. doi:[10.1016/S0140-6736\(18\)33137-4](https://doi.org/10.1016/S0140-6736(18)33137-4)
- Kim, R. S., Song, N., Gavin, P. G., Salgado, R., Bandos, H., Kos, Z., . . . Pogue-Geile, K. L. (2019). Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.. *J Natl Cancer Inst*. doi:[10.1093/jnci/djz032](https://doi.org/10.1093/jnci/djz032)
- Jayasekera, J., Schechter, C. B., Sparano, J. A., Jagsi, R., White, J., Chapman, J. A. W., . . . Mandelblatt, J. (2018). Effects of radiotherapy in early-stage, low-recurrence risk, hormone-sensitive breast cancer. *Journal of the National Cancer Institute*, 110(12). doi:[10.1093/jnci/djy128](https://doi.org/10.1093/jnci/djy128)
- Ingle, J. N., Kalari, K. R., Wickerham, D. L., Von Minckwitz, G., Fasching, P. A., Furukawa, Y., . . . Weinshilboum, R. M. (2018). Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. *Pharmacogenetics and Genomics*, 28(6), 147-152. doi:[10.1097/FPC.0000000000000337](https://doi.org/10.1097/FPC.0000000000000337)
- Asselain, B., Barlow, W., Bartlett, J., Bergh, J., Bergsten-Nordström, E., Bliss, J., . . . von Minckwitz, G. (2018).

- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. *The Lancet Oncology*, 19(1), 27-39. doi:[10.1016/S1470-2045\(17\)30777-5](https://doi.org/10.1016/S1470-2045(17)30777-5)
- Geyer, C. E., Tang, G., Mamounas, E. P., Rastogi, P., Paik, S., Shak, S., . . . Wolmark, N. (2018). 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. *NPJ Breast Cancer*, 4, 37. doi:[10.1038/s41523-018-0090-6](https://doi.org/10.1038/s41523-018-0090-6)
- Mamounas, E. P., Tang, G., Paik, S., Baehner, F. L., Liu, Q., Jeong, J. H., . . . Wolmark, N. (2018). 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. *Breast Cancer Research and Treatment*, 168(1), 69-77. doi:[10.1007/s10549-017-4550-8](https://doi.org/10.1007/s10549-017-4550-8)
- Mamounas, E. P., Liu, Q., Paik, S., Baehner, F. L., Tang, G., Jeong, J. H., . . . Wolmark, N. (2017). 21-gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy. *Journal of the National Cancer Institute*, 109(4). doi:[10.1093/jnci/djw259](https://doi.org/10.1093/jnci/djw259)
- Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Zoon, C. K., Kidwell, K. M., . . . Wolmark, N. (2017). The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. *Annals of Surgical Oncology*, 24(7), 1853-1860. doi:[10.1245/s10434-016-5662-9](https://doi.org/10.1245/s10434-016-5662-9)
- Gavin, P. G., Song, N., Rim Kim, S., Lipchik, C., Johnson, N. L., Bandos, H., . . . Pogue-Geile, K. L. (2017). Association of polymorphisms in FCGR2A and FCGR3A with degree of trastuzumab benefit in the adjuvant treatment of ERBB2/HER2-positive breast cancer analysis of the NSABP B-31 trial. *JAMA Oncology*, 3(3), 335-341. doi:[10.1001/jamaoncol.2016.4884](https://doi.org/10.1001/jamaoncol.2016.4884)
- Land, S. R., Walcott, F. L., Liu, Q., Wickerham, D. L., Costantino, J. P., & Ganz, P. A. (2016). Symptoms and QOL as predictors of chemoprevention adherence in NRG oncology/ NSABP trial P-1. *Journal of the National Cancer Institute*, 108(4). doi:[10.1093/jnci/djv365](https://doi.org/10.1093/jnci/djv365)
- Mamounas, E. P., Bandos, H., White, J. R., Julian, T. B., Khan, A. J., Shaitelman, S. F., . . . Wolmark, N. (2016). NRG Oncology/NSABP B-51/RT0G 1304: A phase III clinical trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypNO after neoadjuvant chemotherapy (NC). *CANCER RESEARCH*, 76. doi:[10.1158/1538-7445.SABCS15-OT2-02-02](https://doi.org/10.1158/1538-7445.SABCS15-OT2-02-02)
- Cecchini, R. S., Swain, S. M., Costantino, J. P., Rastogi, P., Jeong, J. H., Anderson, S. J., . . . Wolmark, N. (2016). Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG oncology/NSABP B-30, B-31, B-34, and B-38. *Cancer Epidemiology Biomarkers and Prevention*, 25(1), 51-59. doi:[10.1158/1055-9965.EPI-15-0334-T](https://doi.org/10.1158/1055-9965.EPI-15-0334-T)
- Liu, Q., Tang, G., Costantino, J. P., & Chang, C. C. H. (2016). Robust prediction of the cumulative incidence function under non-proportional subdistribution hazards. *Canadian Journal of Statistics*, 44(2), 127-141. doi:[10.1002/cjs.11280](https://doi.org/10.1002/cjs.11280)
- Ganz, P. A., Cecchini, R. S., Julian, T. B., Margolese, R. G., Costantino, J. P., Vallow, L. A., . . . Wolmark, N. (2016). Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): A randomised, double-blind, phase 3 clinical trial. *The Lancet*, 387(10021), 857-865. doi:[10.1016/S0140-6736\(15\)01169-1](https://doi.org/10.1016/S0140-6736(15)01169-1)
- Margolese, R. G., Cecchini, R. S., Julian, T. B., Ganz, P. A., Costantino, J. P., Vallow, L. A., . . . Wolmark, N. (2016). Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): A randomised, double-blind, phase 3 clinical trial. *The Lancet*, 387(10021), 849-856. doi:[10.1016/S0140-6736\(15\)01168-X](https://doi.org/10.1016/S0140-6736(15)01168-X)
- Bradley, R., Burrett, J., Clarke, M., Davies, C., Duane, F., Evans, V., . . . Wood, W. (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. *The Lancet*, 386(10001), 1341-1352. doi:[10.1016/S0140-6736\(15\)61074-1](https://doi.org/10.1016/S0140-6736(15)61074-1)
- Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Liu, Q., Robidoux, A., . . . Wolmark, N. (2015). Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): Secondary outcomes of a phase 3, randomised controlled trial. *The Lancet Oncology*, 16(9), 1037-1048. doi:[10.1016/S1470-2045\(15\)00041-8](https://doi.org/10.1016/S1470-2045(15)00041-8)

- O'Sullivan, C. C., Bradbury, I., Campbell, C., Spielmann, M., Perez, E. A., Joensuu, H., . . . Gelber, R. D. (2015). Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors ≤ 2 cm: A meta-analysis of the randomized trastuzumab trials. *Journal of Clinical Oncology*, 33(24), 2600-2608. doi:[10.1200/JCO.2015.60.8620](https://doi.org/10.1200/JCO.2015.60.8620)
- Chapman, J. A. W., Costantino, J. P., Dong, B., Margolese, R. G., Pritchard, K. I., Shepherd, L. E., . . . Pollak, M. N. (2015). Octreotide LAR and tamoxifen versus tamoxifen in phase III randomized early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. *Breast Cancer Research and Treatment*, 153(2), 353-360. doi:[10.1007/s10549-015-3547-4](https://doi.org/10.1007/s10549-015-3547-4)
- Gavin, P. G., Song, N., Johnson, N. L., Lipchik, C., Kim, S. -R., Finnigan, M., . . . Pogue-Geile, K. L. (2015). Association of the FCGR2A and FCGR3A genotypes with trastuzumab benefit in NSABP B-31. *CANCER RESEARCH*, 75. doi:[10.1158/1538-7445.AM2015-CT129](https://doi.org/10.1158/1538-7445.AM2015-CT129)
- Margolese, R. G., Cecchini, R. S., Julian, T. B., Ganz, P. A., Costantino, J. P., Vallow, L., . . . Wolmark, N. (2015). Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. *JOURNAL OF CLINICAL ONCOLOGY*, 33(18). Retrieved from <http://gateway.webofknowledge.com/>
- Mamounas, E. P., Bandos, H., White, J. R., Julian, T. B., Khan, A. J., Shaitelman, S. F., . . . Wolmark, N. (2015). NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypN0 after neoadjuvant chemotherapy (NC).. *JOURNAL OF CLINICAL ONCOLOGY*, 33(15). Retrieved from <http://gateway.webofknowledge.com/>
- Tutt, A. N. J., Kaufman, B., Gelber, R. D., Mc Fadden, E., Goessl, C. D., Viale, G., . . . Geyer, C. E. (2015). OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).. *JOURNAL OF CLINICAL ONCOLOGY*, 33(15). doi:[10.1200/jco.2015.33.15_suppl.tps1109](https://doi.org/10.1200/jco.2015.33.15_suppl.tps1109)
- Margolese, R. G., Cecchini, R. S., Julian, T. B., Ganz, P. A., Costantino, J. P., Vallow, L., . . . Wolmark, N. (2015). Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.. *JOURNAL OF CLINICAL ONCOLOGY*, 33(15). Retrieved from <http://gateway.webofknowledge.com/>
- Mamounas, E. P., Bandos, H., White, J. R., Julian, T. B., Khan, A. J., Shaitelman, S. F., . . . Wolmark, N. (2015). Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast radiotherapy post lumpectomy reduce the rate of invasive cancer events in patients with positive axillary nodes who convert to ypN0 af. *CANCER RESEARCH*, 75. doi:[10.1158/1538-7445.SABCS14-OT1-3-02](https://doi.org/10.1158/1538-7445.SABCS14-OT1-3-02)
- Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Liu, Q., Robidoux, A., . . . Wolmark, N. (2015). The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. *CANCER RESEARCH*, 75. doi:[10.1158/1538-7445.SABCS14-PD2-1](https://doi.org/10.1158/1538-7445.SABCS14-PD2-1)
- Mamounas, E. P., Tang, G., Liu, Q., Jeong, J. -H., Julian, T. B., Rastogi, P., . . . Wolmark, N. (2015). Effect of adjuvant systemic therapy in reducing rates of loco-regional recurrence in early-stage breast cancer: Results from nine NSABP randomized phase III trials. *CANCER RESEARCH*, 75. doi:[10.1158/1538-7445.SABCS14-P5-21-01](https://doi.org/10.1158/1538-7445.SABCS14-P5-21-01)
- Pogue-Geile, K. L., Song, N., Jeong, J. H., Gavin, P. G., Kim, S. R., Blackmon, N. L., . . . Paik, S. (2015). Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. *Journal of Clinical Oncology*, 33(12), 1340-1347. doi:[10.1200/JCO.2014.56.2439](https://doi.org/10.1200/JCO.2014.56.2439)
- Coleman, R., Gray, R., Powles, T., Paterson, A., Gnant, M., Bergh, J., . . . Safra, T. (2015). Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. *The Lancet*, 386(10001), 1353-1361. doi:[10.1016/S0140-6736\(15\)60908-4](https://doi.org/10.1016/S0140-6736(15)60908-4)
- Reddy, V. K., Said, L., Sengupta, B., Chetlur, M., Costantino, J. P., Gopinath, A., . . . Vedula, S. (2015). Personalized Learning Pathways: Enabling intervention creation and tracking. *IBM Journal of Research and Development*, 59(6). doi:[10.1147/JRD.2015.2456711](https://doi.org/10.1147/JRD.2015.2456711)
- Mamounas, E. P., Cortazar, P., Zhang, L., Von Minckwitz, G., Mehta, K., Cameron, D. A., . . . Untch, M. (2014). Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC).. *JOURNAL OF CLINICAL ONCOLOGY*,

32(26). doi:[10.1200/jco.2014.32.26_suppl.61](https://doi.org/10.1200/jco.2014.32.26_suppl.61)

- Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., . . . Von Minckwitz, G. (2014). Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. *The Lancet*, *384*(9938), 164-172. doi:[10.1016/S0140-6736\(13\)62422-8](https://doi.org/10.1016/S0140-6736(13)62422-8)
- Land, S. R., Walcott, F. L., Liu, Q., Wickerham, D. L., Costantino, J. P., & Ganz, P. A. (2014). Patient-reported outcomes and behavioral risk factors as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention P-1 trial. *JOURNAL OF CLINICAL ONCOLOGY*, *32*(15). doi:[10.1200/jco.2014.32.15_suppl.1512](https://doi.org/10.1200/jco.2014.32.15_suppl.1512)
- O'Sullivan, C. C. M., Bradbury, I., De Azambuja, E., Perez, E. A., Rastogi, P., Spielmann, M., . . . Gelber, R. D. (2014). Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors <= 2cm: A meta-analysis of the randomized trastuzumab trials. *JOURNAL OF CLINICAL ONCOLOGY*, *32*(15). Retrieved from <http://gateway.webofknowledge.com/>
- Land, S. R., Liu, Q., Wickerham, D. L., Costantino, J. P., & Ganz, P. A. (2014). Cigarette smoking, physical activity, and alcohol consumption as predictors of cancer incidence among women at high risk of breast cancer in the NSABP P-1 trial. *Cancer Epidemiology Biomarkers and Prevention*, *23*(5), 823-832. doi:[10.1158/1055-9965.EPI-13-1105-T](https://doi.org/10.1158/1055-9965.EPI-13-1105-T)
- Klepin, H. D., Geiger, A. M., Bandos, H., Costantino, J. P., Rapp, S. R., Sink, K. M., . . . Espeland, M. A. (2014). Cognitive factors associated with adherence to oral antiestrogen therapy: Results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study. *Cancer Prevention Research*, *7*(1), 161-168. doi:[10.1158/1940-6207.CAPR-13-0165](https://doi.org/10.1158/1940-6207.CAPR-13-0165)
- Jud, S. M., Hatko, R., Maihöfner, C., Bani, M. R., Schrauder, M. G., Lux, M. P., . . . Hein, A. (2014). Comprehensive visualization of paresthesia in breast cancer survivors. *Arch Gynecol Obstet*, *290*(1), 135-141. doi:[10.1007/s00404-014-3164-1](https://doi.org/10.1007/s00404-014-3164-1)
- McGale, P., Taylor, C., Correa, C., Cutter, D., Duane, F., Ewertz, M., . . . Wood, W. (2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. *The Lancet*, *383*(9935), 2127-2135. doi:[10.1016/S0140-6736\(14\)60488-8](https://doi.org/10.1016/S0140-6736(14)60488-8)
- Pogue-Geile, K. L., Kim, C., Jeong, J. H., Tanaka, N., Bandos, H., Gavin, P. G., . . . Paik, S. (2013). Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. *Journal of the National Cancer Institute*, *105*(23), 1782-1788. doi:[10.1093/jnci/djt321](https://doi.org/10.1093/jnci/djt321)
- Siziopikou, K. P., Anderson, S. J., Cobleigh, M. A., Julian, T. B., Arthur, D. W., Zheng, P., . . . Wolmark, N. (2013). Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. *Breast Cancer Research and Treatment*, *142*(2), 415-421. doi:[10.1007/s10549-013-2755-z](https://doi.org/10.1007/s10549-013-2755-z)
- Robidoux, A., Tang, G., Rastogi, P., Geyer, C. E., Azar, C. A., Atkins, J. N., . . . Wolmark, N. (2013). Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): An open-label, randomised phase 3 trial. *The Lancet Oncology*, *14*(12), 1183-1192. doi:[10.1016/S1470-2045\(13\)70411-X](https://doi.org/10.1016/S1470-2045(13)70411-X)
- Swain, S. M., Tang, G., Geyer, C. E., Rastogi, P., Atkins, J. N., Donnellan, P. P., . . . Wolmark, N. (2013). Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: The NSABP B-38 trial. *Journal of Clinical Oncology*, *31*(26), 3197-3204. doi:[10.1200/JCO.2012.48.1275](https://doi.org/10.1200/JCO.2012.48.1275)
- Ingle, J. N., Liu, M., Lawrence Wickerham, D., Schaid, D. J., Wang, L., Mushiroda, T., . . . Weinshilboum, R. M. (2013). Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: Individualized breast cancer prevention. *Cancer Discovery*, *3*(7), 812-825. doi:[10.1158/2159-8290.CD-13-0038](https://doi.org/10.1158/2159-8290.CD-13-0038)
- Cuzick, J., Sestak, I., Bonanni, B., Costantino, J. P., Cummings, S., DeCensi, A., . . . Wickerham, D. L. (2013). Selective oestrogen receptor modulators in prevention of breast cancer: An updated meta-analysis of individual participant data. *The Lancet*, *381*(9880), 1827-1834. doi:[10.1016/S0140-6736\(13\)60140-3](https://doi.org/10.1016/S0140-6736(13)60140-3)
- Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Robidoux, A., Atkins, J. N., . . . Wolmark, N. (2013). Bevacizumab added to neoadjuvant chemotherapy for breast cancer. *Obstetrical and Gynecological Survey*, *68*(3), 201-202. doi:[10.1097/OGX.0b013e3182877729](https://doi.org/10.1097/OGX.0b013e3182877729)
- Kopec, J. A., Colangelo, L. H., Land, S. R., Julian, T. B., Brown, A. M., Anderson, S. J., . . . Ganz, P. A. (2013).

- Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32. *Journal of Supportive Oncology*, 11(1), 22-30.
- Danhauer, S. C., Legault, C., Bandos, H., Kidwell, K., Costantino, J., Vaughan, L., . . . Shumaker, S. (2013). Positive and negative affect, depression, and cognitive processes in the cognition in the study of tamoxifen and raloxifene (Co-STAR) trial. *Aging, Neuropsychology, and Cognition*, 20(5), 532-552. doi:[10.1080/13825585.2012.747671](https://doi.org/10.1080/13825585.2012.747671)
- Cecchini, R. S., Costantino, J. P., Cauley, J. A., Cronin, W. M., Wickerham, D. L., Bandos, H., . . . Wolmark, N. (2012). Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR). *Cancer Prevention Research*, 5(11), 1321-1329. doi:[10.1158/1940-6207.CAPR-12-0273](https://doi.org/10.1158/1940-6207.CAPR-12-0273)
- Amir, E., Cecchini, R. S., Ganz, P. A., Costantino, J. P., Beddows, S., Hood, N., & Goodwin, P. J. (2012). Erratum: 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1 (Breast Cancer Research and Treatment). *Breast Cancer Research and Treatment*, 135(3), 923. doi:[10.1007/s10549-012-2178-2](https://doi.org/10.1007/s10549-012-2178-2)
- Tang, G., Kong, Y., Chang, C. C. H., Kong, L., & Costantino, J. P. (2012). Authors' reply to the letter to the editor on the paper 'Prediction of accrual closure date in multi-center clinical trials with discrete-time Poisson process models'. *Pharmaceutical Statistics*, 11(5), 359-360. doi:[10.1002/pst.1527](https://doi.org/10.1002/pst.1527)
- Paterson, A. H. G., Anderson, S. J., Lembersky, B. C., Fehrenbacher, L., Falkson, C. I., King, K. M., . . . Wolmark, N. (2012). Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): A multicentre, placebo-controlled, randomised trial. *The Lancet Oncology*, 13(7), 734-742. doi:[10.1016/S1470-2045\(12\)70226-7](https://doi.org/10.1016/S1470-2045(12)70226-7)
- Tang, G., Kong, Y., Chang, C. C. H., Kong, L., & Costantino, J. P. (2012). Prediction of accrual closure date in multi-center clinical trials with discrete-time Poisson process models. *Pharmaceutical Statistics*, 11(5), 351-356. doi:[10.1002/pst.1506](https://doi.org/10.1002/pst.1506)
- Amir, E., Cecchini, R. S., Ganz, P. A., Costantino, J. P., Beddows, S., Hood, N., & Goodwin, P. J. (2012). 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. *Breast Cancer Research and Treatment*, 133(3), 1077-1088. doi:[10.1007/s10549-012-2012-x](https://doi.org/10.1007/s10549-012-2012-x)
- Chapman, J. -A. W., Costantino, J. P., Dong, B., Margolese, R. G., Pritchard, K. I., Shepherd, L. E., . . . Pollak, M. N. (2012). Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29. *JOURNAL OF CLINICAL ONCOLOGY*, 30(15). Retrieved from <http://gateway.webofknowledge.com/>
- Fehrenbacher, L., Jeong, J. -H., Rastogi, P., Geyer, C. E., Paik, S., Ganz, P. A., . . . Wolmark, N. (2012). NSABP B-47: A phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk, node-negative, HER2-low invasive breast cancer. *JOURNAL OF CLINICAL ONCOLOGY*, 30(15). Retrieved from <http://gateway.webofknowledge.com/>
- Allred, D. C., Anderson, S. J., Paik, S., Wickerham, D. L., Nagtegaal, I. D., Swain, S. M., . . . Wolmark, N. (2012). Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: A study based on NSABP protocol B-24. *Journal of Clinical Oncology*, 30(12), 1268-1273. doi:[10.1200/JCO.2010.34.0141](https://doi.org/10.1200/JCO.2010.34.0141)
- Tanaka, N., Jeong, J. -H., Gavin, P. G., Pogue-Geile, K. L., Paik, S., & Costantino, J. P. (2012). Graphical method to predict drug response using genomic biomarkers with nonlinear interaction effect. *CANCER RESEARCH*, 72. doi:[10.1158/1538-7445.AM2012-2711](https://doi.org/10.1158/1538-7445.AM2012-2711)
- Cecchini, R. S., Costantino, J. P., Cauley, J. A., Cronin, W. M., Wickerham, D. L., Land, S. R., . . . Wolmark, N. (2012). Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. *Cancer Prevention Research*, 5(4), 583-592. doi:[10.1158/1940-6207.CAPR-11-0482](https://doi.org/10.1158/1940-6207.CAPR-11-0482)
- Albain, K., Anderson, S., Arriagada, R., Barlow, W., Bergh, J., Bliss, J., . . . Wood, W. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. *The Lancet*, 379(9814), 432-444. doi:[10.1016/S0140-6736\(11\)61625-5](https://doi.org/10.1016/S0140-6736(11)61625-5)

- Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Robidoux, A., Atkins, J. N., . . . Wolmark, N. (2012). Bevacizumab added to neoadjuvant chemotherapy for breast cancer. *New England Journal of Medicine*, 366(4), 310-320. doi:[10.1056/NEJMoa1111097](https://doi.org/10.1056/NEJMoa1111097)
- Schaid, D. J., Sinnwell, J. P., Jenkins, G. D., McDonnell, S. K., Ingle, J. N., Kubo, M., . . . Weinshilboum, R. M. (2012). Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies. *Genetic Epidemiology*, 36(1), 3-16. doi:[10.1002/gepi.20632](https://doi.org/10.1002/gepi.20632)
- Fehrenbacher, L., Jeong, J. -H., Rastogi, P., Geyer, C. E., Paik, S., Ganz, P. A., . . . Wolmark, N. (2011). NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer. *CANCER RESEARCH*, 71. doi:[10.1158/0008-5472.SABCS11-OT1-02-07](https://doi.org/10.1158/0008-5472.SABCS11-OT1-02-07)
- Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Andre, R., Atkins, J. N., . . . Wolmark, N. (2011). The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy: NSABP Protocol B-40. *CANCER RESEARCH*, 71. doi:[10.1158/0008-5472.SABCS11-P007-08](https://doi.org/10.1158/0008-5472.SABCS11-P007-08)
- Julian, T. B., Vicini, F. A., Costantino, J. P., Arthur, D. W., Kidwell, K. M., Land, S. R., . . . Wolmark, N. (2011). Boost Radiation Therapy Not of Value in Reducing IBTR of Invasive or Noninvasive Breast Cancers for Patients with DCIS: Results from the NSABP B-24 Trial. *CANCER RESEARCH*, 71. doi:[10.1158/0008-5472.SABCS11-P3-13-01](https://doi.org/10.1158/0008-5472.SABCS11-P3-13-01)
- Runowicz, C. D., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Ford, L. G., . . . Wolmark, N. (2011). Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). *American Journal of Obstetrics and Gynecology*, 205(6), 535.e1-535.e5. doi:[10.1016/j.ajog.2011.06.067](https://doi.org/10.1016/j.ajog.2011.06.067)
- Tang, G., Cuzick, J., Costantino, J. P., Dowsett, M., Forbes, J. F., Crager, M., . . . Wolmark, N. (2011). Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: Recurrence score alone and integrated with pathologic and clinical factors. *Journal of Clinical Oncology*, 29(33), 4365-4372. doi:[10.1200/JCO.2011.35.3714](https://doi.org/10.1200/JCO.2011.35.3714)
- Kim, C., Tang, G., Pogue-Geile, K. L., Costantino, J. P., Baehner, F. L., Baker, J., . . . Paik, S. (2011). Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. *Journal of Clinical Oncology*, 29(31), 4160-4167. doi:[10.1200/JCO.2010.32.9615](https://doi.org/10.1200/JCO.2010.32.9615)
- Goetz, M. P., Schaid, D. J., Wickerham, D. L., Safgren, S., Mushiroda, T., Kubo, M., . . . Ames, M. M. (2011). Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: Results from the NSABP P1 and P2 clinical trials. *Clinical Cancer Research*, 17(21), 6944-6951. doi:[10.1158/1078-0432.CCR-11-0860](https://doi.org/10.1158/1078-0432.CCR-11-0860)
- Danhauer, S. C., Legault, C., Costantino, J. P., Avis, N. E., Rapp, S., Coker, L. H., . . . Shumaker, S. A. (2011). AFFECT, DEPRESSION, AND COGNITION IN COGNITION IN THE STUDY OF TAMOXIFEN AND RALOXIFENE (CO-STAR). *GERONTOLOGIST*, 51, 292. Retrieved from <http://gateway.webofknowledge.com/>
- Land, S. R., Cronin, W. M., Wickerham, D. L., Costantino, J. P., Christian, N. J., Klein, W. M. P., & Ganz, P. A. (2011). Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the national surgical adjuvant breast and bowel project P-1 breast cancer prevention trial. *Cancer Prevention Research*, 4(9), 1393-1400. doi:[10.1158/1940-6207.CAPR-11-0172](https://doi.org/10.1158/1940-6207.CAPR-11-0172)
- Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Masuda, H., . . . Delozier, T. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. *The Lancet*, 378(9793), 771-784. doi:[10.1016/S0140-6736\(11\)60993-8](https://doi.org/10.1016/S0140-6736(11)60993-8)
- Freedman, A. N., Yu, B., Gail, M. H., Costantino, J. P., Graubard, B. I., Vogel, V. G., . . . McCaskill-Stevens, W. (2011). Development of a Benefit/Risk Assessment Tool for Breast Cancer Chemoprevention. *PHARMACOEPIDEMIOLOGY AND DRUG SAFETY*, 20, S273-S274. Retrieved from <http://gateway.webofknowledge.com/>
- Matsuno, R. K., Costantino, J. P., Ziegler, R. G., Anderson, G. L., Li, H., Pee, D., & Gail, M. H. (2011). Projecting individualized absolute invasive breast cancer risk in Asian and pacific islander American women.

- Journal of the National Cancer Institute*, 103(12), 951-961. doi:[10.1093/jnci/djr154](https://doi.org/10.1093/jnci/djr154)
- Freedman, A. N., Yu, B., Gail, M. H., Costantino, J. P., Graubard, B. I., Vogel, V. G., . . . McCaskill-Stevens, W. (2011). Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. *Journal of Clinical Oncology*, 29(17), 2327-2333. doi:[10.1200/JCO.2010.33.0258](https://doi.org/10.1200/JCO.2010.33.0258)
- Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Robidoux, A., Atkins, J. N., . . . Wolmark, N. (2011). The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. *JOURNAL OF CLINICAL ONCOLOGY*, 29(15). Retrieved from <http://gateway.webofknowledge.com/>
- Shen, K., Tang, G., Costantino, J. P., Anderson, S. J., Kim, C., Pogue-Geile, K. L., . . . Wolmark, N. (2011). Multigene predictors developed on breast cancer cell lines to predict patient chemotherapy response: A validation study on the NSABP B-27 trial. *JOURNAL OF CLINICAL ONCOLOGY*, 29(15). doi:[10.1200/jco.2011.29.15_suppl.1029](https://doi.org/10.1200/jco.2011.29.15_suppl.1029)
- Tang, G., Shak, S., Paik, S., Anderson, S. J., Costantino, J. P., Geyer, C. E., . . . Wolmark, N. (2011). Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and adjuvant! for women with node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. *Breast Cancer Research and Treatment*, 127(1), 133-142. doi:[10.1007/s10549-010-1331-z](https://doi.org/10.1007/s10549-010-1331-z)
- Liu, M., Wang, L., Schaid, D., Wickerham, D. L., Costantino, J. P., Goetz, M. P., . . . Weinshilboum, R. M. (2011). Breast cancer prevention and selective estrogen response modulators (SERMs): Pharmacogenomics and differential estrogen and SERM regulation of BRCA1 and BRCA2 expression. *CANCER RESEARCH*, 71. doi:[10.1158/1538-7445.AM2011-4727](https://doi.org/10.1158/1538-7445.AM2011-4727)
- Ganz, P. A., Land, S. R., Geyer, C. E., Cecchini, R. S., Costantino, J. P., Pajon, E. R., . . . Swain, S. M. (2011). Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. *Journal of Clinical Oncology*, 29(9), 1110-1116. doi:[10.1200/JCO.2010.29.7689](https://doi.org/10.1200/JCO.2010.29.7689)
- Wapnir, I. L., Dignam, J. J., Fisher, B., Mamounas, E. P., Anderson, S. J., Julian, T. B., . . . Wolmark, N. (2011). Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. *Journal of the National Cancer Institute*, 103(6), 478-488. doi:[10.1093/jnci/djr027](https://doi.org/10.1093/jnci/djr027)
- Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., . . . Wood, W. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10 801 women in 17 randomised trials. *The Lancet*, 378(9804), 1707-1716. doi:[10.1016/S0140-6736\(11\)61629-2](https://doi.org/10.1016/S0140-6736(11)61629-2)
- Ingle, J. N., Liu, M., Wickerham, D. L., Schaid, D. J., Mushiroda, T., Kubo, M., . . . Weinshilboum, R. (2010). Genome-Wide Associations of Breast Events and Functional Genomic Studies in High-Risk Women Receiving Tamoxifen or Raloxifene on NSABP P1 and P2 Prevention Trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration. *CANCER RESEARCH*, 70. doi:[10.1158/0008-5472.SABCS10-PD05-02](https://doi.org/10.1158/0008-5472.SABCS10-PD05-02)
- Swain, S. M., Jeong, J. -H., Jr, G. C. E., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., . . . Wolmark, N. (2010). Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer. *OBSTETRICAL & GYNECOLOGICAL SURVEY*, 65(11), 710-712. doi:[10.1097/OGX.0b013e318202211d](https://doi.org/10.1097/OGX.0b013e318202211d)
- Krag, D. N., Anderson, S. J., Julian, T. B., Brown, A. M., Harlow, S. P., Costantino, J. P., . . . Wolmark, N. (2010). Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. *The Lancet Oncology*, 11(10), 927-933. doi:[10.1016/S1470-2045\(10\)70207-2](https://doi.org/10.1016/S1470-2045(10)70207-2)
- Swain, S. M., Jeong, J. H., Geyer, C. E., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., . . . Gluz, O. (2010). Chemotherapy induced amenorrhea as an indicator of better survival in early breast cancer. *Breast Care*, 5(5), 365-366. doi:[10.1159/000322294](https://doi.org/10.1159/000322294)
- Land, S. R., Kopec, J. A., Julian, T. B., Brown, A. M., Anderson, S. J., Krag, D. N., . . . Ganz, P. A. (2010). Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. *Journal of Clinical Oncology*, 28(25), 3929-3936. doi:[10.1200/JCO.2010.28.2491](https://doi.org/10.1200/JCO.2010.28.2491)

- Ashikaga, T., Krag, D. N., Land, S. R., Julian, T. B., Anderson, S. J., Brown, A. M., . . . Wolmark, N. (2010). Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. *Journal of Surgical Oncology*, 102(2), 111-118. doi:[10.1002/jso.21535](https://doi.org/10.1002/jso.21535)
- Yang, S. X., Costantino, J. P., Kim, C., Mamounas, E. P., Nguyen, D., Jeong, J. H., . . . Swain, S. M. (2010). Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. *Journal of Clinical Oncology*, 28(18), 2974-2981. doi:[10.1200/JCO.2009.26.1602](https://doi.org/10.1200/JCO.2009.26.1602)
- Swain, S. M., Jeong, J. H., Geyer, C. E., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., . . . Wolmark, N. (2010). Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. *New England Journal of Medicine*, 362(22), 2053-2065. doi:[10.1056/NEJMoa0909638](https://doi.org/10.1056/NEJMoa0909638)
- Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., . . . Wolmark, N. (2010). Update of the national surgical adjuvant breast and bowel project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: Preventing breast cancer. *Cancer Prevention Research*, 3(6), 696-706. doi:[10.1158/1940-6207.CAPR-10-0076](https://doi.org/10.1158/1940-6207.CAPR-10-0076)
- Land, S. R., Christian, N., Cronin, W. M., Wickerham, D., Costantino, J. P., & Ganz, P. A. (2010). Cigarette smoking, fitness, and obesity as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention Trial (BCPT).. *JOURNAL OF CLINICAL ONCOLOGY*, 28(15). doi:[10.1200/jco.2010.28.15_suppl.1524](https://doi.org/10.1200/jco.2010.28.15_suppl.1524)
- Wolmark, N., Curran, W. J., Vicini, F., White, J., Costantino, J. P., Arthur, D., . . . Parda, D. S. (2010). Response to "Unacceptable Cosmesis in a Protocol Investigating Intensity-Modulated Radiotherapy With Active Breathing Control for Accelerated Partial-Breast Irradiation" (Int J Radiat Oncol Biol Phys 2010;76:71-78) and "Toxicity of Three-Dimensional Conformal Radiotherapy for Accelerated Partial Breast Irradiation" Int J Radiat Oncol Biol Phys 2009;75:1290-1296). *International Journal of Radiation Oncology Biology Physics*, 77(1), 317. doi:[10.1016/j.ijrobp.2009.12.033](https://doi.org/10.1016/j.ijrobp.2009.12.033)
- Klepin, H. D., Geiger, A. M., Costantino, J. P., Sink, K. M., Lawrence, J. A., & Espeland, M. A. (2010). Association between domain-specific cognitive function and adherence to oral anti-cancer therapy: Results from Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR).. *JOURNAL OF THE AMERICAN GERIATRICS SOCIETY*, 58, 86-87. Retrieved from <http://gateway.webofknowledge.com/>
- Mamounas, E. P., Tang, G., Fisher, B., Paik, S., Shak, S., Costantino, J. P., . . . Wolmark, N. (2010). Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. *Journal of Clinical Oncology*, 28(10), 1677-1683. doi:[10.1200/JCO.2009.23.7610](https://doi.org/10.1200/JCO.2009.23.7610)
- Dunn, B. K., Greene, M. H., Kelley, J. M., Costantino, J. P., Clifford, R. J., Hu, Y., . . . Buetow, K. H. (2010). Novel pathway analysis of genomic polymorphism-cancer risk interaction in the breast cancer prevention trial. *International Journal of Molecular Epidemiology and Genetics*, 1(4), 332-349.
- Wilkinson, N. W., Yothers, G., Lopa, S., Costantino, J. P., Petrelli, N. J., & Wolmark, N. (2010). Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage ii and stage iii colon cancer: Pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. *Annals of Surgical Oncology*, 17(4), 959-966. doi:[10.1245/s10434-009-0881-y](https://doi.org/10.1245/s10434-009-0881-y)
- Eng-wong, J., Costantino, J. P., & Swain, S. M. (2010). The impact of systemic therapy following ductal carcinoma in situ. *Journal of the National Cancer Institute - Monographs*, (41), 200-203. doi:[10.1093/jncimonographs/lgq021](https://doi.org/10.1093/jncimonographs/lgq021)
- Vogel, V. G., Costantino, J. P., Lawrence, W. D., Mccaskill-stevens, W., Clarfeld, R. B., Grant, M. D., & Wolmark, N. (2010). Carcinoma in situ outcomes in National surgical Adjuvant breast and Bowel Project breast cancer chemoprevention trials. *Journal of the National Cancer Institute - Monographs*, (41), 181-186. doi:[10.1093/jncimonographs/lgq041](https://doi.org/10.1093/jncimonographs/lgq041)
- Davidson, N., Gelber, R., Piccart, M., Pruneri, G., Pritchard, K., Ravdin, P., . . . Cuzick, J. (2010). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. *Journal of the National Cancer Institute - Monographs*, 41, 162-177. doi:[10.1093/jncimonographs/lgq039](https://doi.org/10.1093/jncimonographs/lgq039)
- Anderson, S. J., Wapnir, I., Dignam, J. J., Fisher, B., Mamounas, E. P., Jeong, J. H., . . . Wolmark, N. (2009). Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. *Journal of Clinical Oncology*, 27(15), 2466-2473. doi:[10.1200/JCO.2008.19.8424](https://doi.org/10.1200/JCO.2008.19.8424)

- Kramer, B. S., Hagerty, K. L., Justman, S., Somerfield, M. R., Albertsen, P. C., Blot, W. J., . . . Schellhammer, P. (2009). Use of 5- α -reductase inhibitors for prostate cancer chemoprevention: American society of clinical oncology/American Urological Association 2008 clinical practice guideline summary. *Journal of Oncology Practice*, 5(3), 127-129. doi:[10.1200/JOP.0938503](https://doi.org/10.1200/JOP.0938503)
- Kramer, B. S., Hagerty, K. L., Justman, S., Somerfield, M. R., Albertsen, P. C., Blot, W. J., . . . Schellhammer, P. (2009). Use of 5 α -Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. *Journal of Urology*, 181(4), 1642-1657. doi:[10.1016/j.juro.2009.01.071](https://doi.org/10.1016/j.juro.2009.01.071)
- Kramer, B. S., Hagerty, K. L., Justman, S., Somerfield, M. R., Albertsen, P. C., Blot, W. J., . . . Schellhammer, P. (2009). Use of 5- α -reductase inhibitors for prostate cancer chemoprevention: American society of clinical oncology/American Urological Association 2008 clinical practice guideline. *Journal of Clinical Oncology*, 27(9), 1502-1516. doi:[10.1200/JCO.2008.16.9599](https://doi.org/10.1200/JCO.2008.16.9599)
- Wickerham, D. L., Costantino, J. P., Vogel, V. G., Cronin, W. M., Cecchini, R. S., Ford, L. G., & Wolmark, N. (2009). The use of tamoxifen and raloxifene for the prevention of breast cancer.. *Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer*, 181, 113-119.
- Swain, S. M., Land, S. R., Ritter, M. W., Costantino, J. P., Cecchini, R. S., Mamounas, E. P., . . . Ganz, P. A. (2009). Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide- followed-by-docetaxel arm of NSABP B-30 trial. *Breast Cancer Research and Treatment*, 113(2), 315-320. doi:[10.1007/s10549-008-9937-0](https://doi.org/10.1007/s10549-008-9937-0)
- Shen, Y., Costantino, J. P., & Qin, J. (2008). Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer. *Journal of the National Cancer Institute*, 100(20), 1448-1453. doi:[10.1093/jnci/djn320](https://doi.org/10.1093/jnci/djn320)
- Ross, D. T., Kim, C. Y., Tang, G., Bohn, O. L., Beck, R. A., Ring, B. Z., . . . Wolmark, N. (2008). Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20Trials. *Clinical Cancer Research*, 14(20), 6602-6609. doi:[10.1158/1078-0432.CCR-08-0647](https://doi.org/10.1158/1078-0432.CCR-08-0647)
- Wickerham, D. L., O'Connell, M. J., Costantino, J. P., Cronin, W. M., Paik, S., Geyer, C. E., . . . Wolmark, N. (2008). The Half Century of Clinical Trials of the National Surgical Adjuvant Breast and Bowel Project. *Seminars in Oncology*, 35(5), 522-529. doi:[10.1053/j.seminoncol.2008.07.005](https://doi.org/10.1053/j.seminoncol.2008.07.005)
- Wapnir, I. L., Aebi, S., Geyer, C. E., Zahrieh, D., Gelber, R. D., Anderson, S. J., . . . Wolmark, N. (2008). A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. *Clinical Breast Cancer*, 8(3), 287-292. doi:[10.3816/CBC.2008.n.035](https://doi.org/10.3816/CBC.2008.n.035)
- Cella, D., Land, S. R., Chang, C. H., Day, R., Costantino, J. P., Wolmark, N., & Ganz, P. A. (2008). Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): Psychometric properties of a new measure of symptoms for midlife women. *Breast Cancer Research and Treatment*, 109(3), 515-526. doi:[10.1007/s10549-007-9682-9](https://doi.org/10.1007/s10549-007-9682-9)
- Liang, H., Lo, S. S., Ye, F., Costantino, J. P., Hudson, A., & Vogel, V. G. (2008). Correlation of serum sex hormone levels with the Gail model risk of breast cancer in postmenopausal women. *JOURNAL OF CLINICAL ONCOLOGY*, 26(15). doi:[10.1200/jco.2008.26.15_suppl.1517](https://doi.org/10.1200/jco.2008.26.15_suppl.1517)
- Wang, J., Anderson, S. J., Costantino, J. P., Mamounas, E. P., Hassett, J. M., & Wolmark, N. (2008). Should log odds of positive lymph node be incorporated into AJCC TNM breast cancer staging system?. *JOURNAL OF CLINICAL ONCOLOGY*, 26(15). doi:[10.1200/jco.2008.26.15_suppl.11037](https://doi.org/10.1200/jco.2008.26.15_suppl.11037)
- Julian, T. B., Land, S. R., Wang, Y., Vicini, F., Arthur, D., Mamounas, E. P., . . . Wolmark, N. (2008). Is boost therapy necessary in the treatment of DCIS?. *JOURNAL OF CLINICAL ONCOLOGY*, 26(15). Retrieved from <http://gateway.webofknowledge.com/>
- Gail, M. H., Bernstein, L., Costantino, J. P., Pee, D., & Ursin, G. (2008). Response: Re: Projecting individualized absolute invasive breast cancer risk in African American women. *Journal of the National Cancer Institute*, 100(9), 684. doi:[10.1093/jnci/djn110](https://doi.org/10.1093/jnci/djn110)
- Mamounas, E. P., Jeong, J. H., Lawrence Wickerham, D., Smith, R. E., Ganz, P. A., Land, S. R., . . . Wolmark, N. (2008). Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the national surgical adjuvant breast and bowel project B-33 trial. *Journal of Clinical Oncology*, 26(12), 1965-1971. doi:[10.1200/JCO.2007.14.0228](https://doi.org/10.1200/JCO.2007.14.0228)

- Costantino, J. P. (2008). Reminiscence of samuel H. Wieand: The NSABP Years. *Lifetime Data Analysis*, 14(1), 16-17. doi:[10.1007/s10985-007-9067-8](https://doi.org/10.1007/s10985-007-9067-8)
- Jeong, J. H., Jung, S. H., & Costantino, J. P. (2008). Nonparametric inference on median residual life function. *Biometrics*, 64(1), 157-163. doi:[10.1111/j.1541-0420.2007.00826.x](https://doi.org/10.1111/j.1541-0420.2007.00826.x)
- Gail, M. H., Costantino, J. P., Pee, D., Bondy, M., Newman, L., Selvan, M., . . . Bernstein, L. (2007). Projecting individualized absolute invasive breast cancer risk in African American women. *Journal of the National Cancer Institute*, 99(23), 1782-1792. doi:[10.1093/jnci/djm223](https://doi.org/10.1093/jnci/djm223)
- Shen, Y., Qin, J., & Costantino, J. P. (2007). Inference of tamoxifen's effects on prevention of breast cancer from a randomized controlled trial. *Journal of the American Statistical Association*, 102(480), 1235-1244. doi:[10.1198/01621450600001446](https://doi.org/10.1198/01621450600001446)
- Julian, T. B., Anderson, S. J., Fourchette, V., Brown, A. M., Boudros, E., Mamounas, E. P., . . . Wolmark, N. (2007). Is intraoperative cytology of sentinel nodes useful and predictive for non-sentinel axillary nodes? NSABP B-32. *BREAST CANCER RESEARCH AND TREATMENT*, 106, S126. Retrieved from <http://gateway.webofknowledge.com/>
- Land, S. R., Ritter, M. W., Costantino, J. P., Julian, T. B., Cronin, W. M., Haile, S. R., . . . Ganz, P. A. (2007). Compliance with patient-reported outcomes in multicenter clinical trials: Methodologic and practical approaches. *Journal of Clinical Oncology*, 25(32), 5113-5120. doi:[10.1200/JCO.2007.12.1749](https://doi.org/10.1200/JCO.2007.12.1749)
- Fisher, E. R., Costantino, J. P., Leon, M. E., Bandos, H., Palekar, A. S., Fisher, B., & Wolmark, N. (2007). Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21. *Cancer*, 110(9), 1929-1936. doi:[10.1002/cncr.23011](https://doi.org/10.1002/cncr.23011)
- Krag, D. N., Anderson, S. J., Julian, T. B., Brown, A. M., Harlow, S. P., Ashikaga, T., . . . Wolmark, N. (2007). Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. *Lancet Oncology*, 8(10), 881-888. doi:[10.1016/S1470-2045\(07\)70278-4](https://doi.org/10.1016/S1470-2045(07)70278-4)
- Julian, T. B., Land, S. R., Fourchette, V., Haile, S. R., Fisher, E. R., Mamounas, E. P., . . . Wolmark, N. (2007). Is sentinel node biopsy necessary in conservatively treated DCIS?. *Annals of Surgical Oncology*, 14(8), 2202-2208. doi:[10.1245/s10434-007-9353-4](https://doi.org/10.1245/s10434-007-9353-4)
- Fisher, E. R., Land, S. R., Saad, R. S., Fisher, B., Wickerham, D. L., Wang, M., . . . Wolmark, N. (2007). Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. *American Journal of Clinical Pathology*, 128(1), 86-91. doi:[10.1309/WH9LA543NR76Y29J](https://doi.org/10.1309/WH9LA543NR76Y29J)
- Land, S. R., Kopec, J. A., Cecchini, R. S., Ganz, P. A., Wieand, H. S., Colangelo, L. H., . . . Wolmark, N. (2007). Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. *Journal of Clinical Oncology*, 25(16), 2205-2211. doi:[10.1200/JCO.2006.08.6652](https://doi.org/10.1200/JCO.2006.08.6652)
- Hudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J. A. W., . . . Zujewski, J. A. (2007). Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. *Journal of Clinical Oncology*, 25(15), 2127-2132. doi:[10.1200/JCO.2006.10.3523](https://doi.org/10.1200/JCO.2006.10.3523)
- Mamounas, E. P., Lembersky, B., Jeong, J. H., Cronin, W., Harkins, B., Geyer, C., . . . Wolmark, N. (2006). NSABP B-42: A clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. *Clinical Breast Cancer*, 7(5), 416-421. doi:[10.3816/CBC.2006.n.061](https://doi.org/10.3816/CBC.2006.n.061)
- Haller, D. G., O'Connell, M. J., Sargent, D., Costantino, J. P., & Wolmark, N. (2006). Sam Wieand, PhD - In memoriam. *JOURNAL OF CLINICAL ONCOLOGY*, 24(28), 4523-4525. doi:[10.1200/JCO.2006.08.6587](https://doi.org/10.1200/JCO.2006.08.6587)
- Taghian, A. G., Jeong, J. H., Mamounas, E. P., Parda, D. S., Deutsch, M., Costantino, J. P., & Wolmark, N. (2006). Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: Results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. *Journal of Clinical Oncology*, 24(24), 3927-3932. doi:[10.1200/JCO.2006.06.9054](https://doi.org/10.1200/JCO.2006.06.9054)
- Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., . . . Wolmark, N. (2006). Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *Journal of*

- Clinical Oncology*, 24(23), 3726-3734. doi:[10.1200/JCO.2005.04.7985](https://doi.org/10.1200/JCO.2005.04.7985)
- El-Saed, A., Kuller, L. H., Newman, A. B., Lopez, O., Costantino, J., McTigue, K., . . . Kronmal, R. (2006). Factors associated with geographic variations in stroke incidence among older populations in four US communities. *Stroke*, 37(8), 1980-1985. doi:[10.1161/01.STR.0000231454.77745.d9](https://doi.org/10.1161/01.STR.0000231454.77745.d9)
- El-Saed, A., Kuller, L. H., Newman, A. B., Lopez, O., Costantino, J., McTigue, K., . . . Kronmal, R. (2006). Geographic variations in stroke incidence and mortality among older populations in four US communities. *Stroke*, 37(8), 1975-1979. doi:[10.1161/01.STR.0000231453.98473.67](https://doi.org/10.1161/01.STR.0000231453.98473.67)
- Abramson, N., Costantino, J. P., Garber, J. E., Berliner, N., Wickerham, D. L., & Wolmark, N. (2006). Effect of factor V Leiden and prothrombin G20210→A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. *Journal of the National Cancer Institute*, 98(13), 904-910. doi:[10.1093/jnci/djj262](https://doi.org/10.1093/jnci/djj262)
- Wickerham, D. L., Costantino, J. P., Mamounas, E. P., & Julian, T. B. (2006). The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel Project. *World Journal of Surgery*, 30(7), 1138-1146. doi:[10.1007/s00268-005-0552-5](https://doi.org/10.1007/s00268-005-0552-5)
- Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., . . . Wolmark, N. (2006). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *Journal of the American Medical Association*, 295(23), 2727-2741. doi:[10.1001/jama.295.23.joc60074](https://doi.org/10.1001/jama.295.23.joc60074)
- Land, S. R., Wickerham, D. L., Costantino, J. P., Ritter, M. W., Vogel, V. G., Lee, M., . . . Ganz, P. A. (2006). Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *Journal of the American Medical Association*, 295(23), 2742-2751. doi:[10.1001/jama.295.23.joc60075](https://doi.org/10.1001/jama.295.23.joc60075)
- Wickerham, D. L., Costantino, J. P., Vogel, V., Cronin, W., Cecchini, R., Atkins, J., . . . Wolmark, N. (2006). The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study. *JOURNAL OF CLINICAL ONCOLOGY*, 24(18), 2S. Retrieved from <http://gateway.webofknowledge.com/>
- Ganz, P. A., Land, S. R., Wickerham, D. L., Lee, M., Ritter, M., Vogel, V., . . . Wolmark, N. (2006). The study of tamoxifen and raloxifene (STAR): First report of patient-reported outcomes (PROs) from the NSABP P-2 Breast Cancer Prevention Study. *JOURNAL OF CLINICAL ONCOLOGY*, 24(18), 933S. Retrieved from <http://gateway.webofknowledge.com/>
- Ganz, P. A., Land, S. R., Wickerham, D. L., Lee, M., Ritter, M., Vogel, V., . . . Wolmark, N. (2006). The study of tamoxifen and raloxifene (STAR): First report of patient-reported outcomes (PROs) from the NSABP P-2 Breast Cancer Prevention Study. *JOURNAL OF CLINICAL ONCOLOGY*, 24(18), 18S. Retrieved from <http://gateway.webofknowledge.com/>
- Fisher, B., & Costantino, J. P. (2006). Re: Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study - Response. *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*, 98(9), 643-644. doi:[10.1093/jnci/djj168](https://doi.org/10.1093/jnci/djj168)
- Chalas, E., Costantino, J. P., Wickerham, D. L., & Runowicz, C. D. (2006). Reply. *American Journal of Obstetrics and Gynecology*, 194(4), 1205. doi:[10.1016/j.ajog.2005.07.063](https://doi.org/10.1016/j.ajog.2005.07.063)
- Beattie, M. S., Costantino, J. P., Cummings, S. R., Wickerham, D. L., Vogel, V. G., Dowsett, M., . . . Hankinson, S. E. (2006). Endogenous sex hormones, breast cancer risk, and tamoxifen response: An ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). *Journal of the National Cancer Institute*, 98(2), 110-115. doi:[10.1093/jnci/djj011](https://doi.org/10.1093/jnci/djj011)
- Kopec, J. A., Land, S. R., Cecchini, R. S., Ganz, P. A., Cella, D., Costantino, J. P., . . . Wolmark, N. (2006). Validation of a Self-Reported Neurotoxicity Scale in Patients with Operable Colon Cancer Receiving Oxaliplatin. *J Support Oncol*, 4(8), W1-W8.
- Modugno, F., Ngo, D. L., Allen, G. O., Kuller, L. H., Ness, R. B., Vogel, V. G., . . . Cauley, J. A. (2006). Breast cancer risk factors and mammographic breast density in women over age 70. *Breast Cancer Research and Treatment*, 97(2), 157-166. doi:[10.1007/s10549-005-9105-8](https://doi.org/10.1007/s10549-005-9105-8)
- El-Saed, A., Kuller, L., Newman, A., Lopez, O., Costantino, J. P., Mctigue, K., . . . Kronmal, R. (2006). Geographic variations in stroke incidence and mortality among older populations in four U.S. communities. *Stroke*, 37(8), 1975-79.

- Jeong, J. H., & Costantino, J. P. (2006). Application of smoothing methods to evaluate treatment-prognostic factor interactions in breast cancer data. *Cancer Investigation*, 24(3), 288-293. doi:[10.1080/07357900600633841](https://doi.org/10.1080/07357900600633841)
- Kim, C., Tang, G., Baehner, F. L., Watson, D., Costantino, J. P., Paik, S., . . . Wolmark, N. (2006). A comparison of estrogen receptor (ER) measurement by three methods in node negative, estrogen receptor (ER) positive breast cancer: ligand binding (LB), immunohistochemistry (IHC), and quantitative RT-PC.. *BREAST CANCER RESEARCH AND TREATMENT*, 100, S162-S163. Retrieved from <http://gateway.webofknowledge.com/>
- Julian, B., Fourchotte, V., Anderson, S., Mamounas, T., Costantino, J. P., Boudros, E., & Wolmark, N. (2006). Predictive factors that identify patients not requiring a sentinel node biopsy: Continued analysis of the NSABP B-32 sentinel node trial.. *BREAST CANCER RESEARCH AND TREATMENT*, 100, S80-S81. Retrieved from <http://gateway.webofknowledge.com/>
- Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Masuda, H., . . . Gordilho, J. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. *Lancet*, 366(9503), 2087-2106. doi:[10.1016/S0140-6736\(05\)67887-7](https://doi.org/10.1016/S0140-6736(05)67887-7)
- Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., . . . Wolmark, N. (2005). Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *Journal of the National Cancer Institute*, 97(22), 1652-1662. doi:[10.1093/jnci/dji372](https://doi.org/10.1093/jnci/dji372)
- Gorin, M. B., Costantino, J. P., Kulacoglu, D. N., Demirci, F. Y. K., Wickerham, D. L., Fisher, B., & Wolmark, N. (2005). Is tamoxifen a risk factor for retinal vaso-occlusive disease?. *Retina*, 25(4), 523-526. doi:[10.1097/00006982-200506000-00023](https://doi.org/10.1097/00006982-200506000-00023)
- Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Masuda, H., . . . Andersen, K. W. (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. *Lancet*, 365(9472), 1687-1717. doi:[10.1016/S0140-6736\(05\)66544-0](https://doi.org/10.1016/S0140-6736(05)66544-0)
- Chalas, E., Costantino, J. P., Wickerham, D. L., Wolmark, N., Lewis, G. C., Bergman, C., & Runowicz, C. D. (2005). Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. *American Journal of Obstetrics and Gynecology*, 192(4), 1230-1237. doi:[10.1016/j.ajog.2004.12.083](https://doi.org/10.1016/j.ajog.2004.12.083)
- Berger, A. S., & Kaplan, H. J. (1992). Clinical experience with the surgical removal of subfoveal neovascular membranes. Short-term postoperative results.. *Ophthalmology*, 99(6), 969-975. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/1630786>
- Wang, J., Costantino, J. P., Tan-Chiu, E., Wickerham, D. L., Paik, S., & Wolmark, N. (2004). Lower-category benign breast disease and the risk of invasive breast cancer. *Journal of the National Cancer Institute*, 96(8), 616-620. doi:[10.1093/jnci/djhs105](https://doi.org/10.1093/jnci/djhs105)
- Agatista, P. K., Ness, R. B., Roberts, J. M., Costantino, J. P., Kuller, L. H., & McLaughlin, M. K. (2004). Impairment of endothelial function in women with a history of preeclampsia: An indicator of cardiovascular risk. *American Journal of Physiology - Heart and Circulatory Physiology*, 286(4 55-4). doi:[10.1152/ajpheart.00298.2003](https://doi.org/10.1152/ajpheart.00298.2003)
- Martino, S., Costantino, J., McNabb, M., Mershon, J., Bryant, K., Powles, T., & Secret, R. J. (2004). The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials. *Oncologist*, 9(2), 116-125. doi:[10.1634/theoncologist.9-2-116](https://doi.org/10.1634/theoncologist.9-2-116)
- Beattie, M. S., Costantino, J. P., Vogel, V., Wickerham, D. L., Wolmark, N., Dowsett, M., . . . Cummings, S. R. (2004). Endogenous sex hormones and response to tamoxifen: an ancillary study in the breast cancer prevention trial (P-01). *BREAST CANCER RESEARCH AND TREATMENT*, 88, S14. Retrieved from <http://gateway.webofknowledge.com/>
- Costantino, J. P. (2003). Tamoxifen reduced the incidence of breast cancer in women at increased risk, but had more adverse events. *Evidence-based Obstetrics and Gynecology*, 5(3), 141-142. doi:[10.1016/S1361-259X\(03\)00101-6](https://doi.org/10.1016/S1361-259X(03)00101-6)
- Wang, H. E., Kupas, D. F., Paris, P. M., Bates, R. R., Costantino, J. P., & Yealy, D. M. (2003). Multivariate predictors of failed prehospital endotracheal intubation. *ACADEMIC EMERGENCY MEDICINE*, 10(7), 717-724. doi:[10.1197/aemj.10.7.717](https://doi.org/10.1197/aemj.10.7.717)

- Tan-Chiu, E., Wang, J. P., Costantino, J. P., Paik, S., Butch, C., Wickerham, D. L., . . . Wolmark, N. (2003). Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*, 95(4), 302-307. doi:[10.1093/jnci/95.4.302](https://doi.org/10.1093/jnci/95.4.302)
- Vogel, V. G., Costantino, J. P., Wickerham, D. L., & Cronin, W. M. (2003). National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. *Clin Cancer Res*, 9(1 Pt 2), 495S-501S. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/12538506>
- Cushman, M., Costantino, J. P., Bovill, E. G., Wickerham, D. L., Buckley, L., Roberts, J. D., & Krag, D. N. (2003). Effect of tamoxifen on venous thrombosis risk factors in women without cancer: The Breast Cancer Prevention Trial. *British Journal of Haematology*, 120(1), 109-116. doi:[10.1046/j.1365-2141.2003.03976.x](https://doi.org/10.1046/j.1365-2141.2003.03976.x)
- Vogel, V. G., Costantino, J. P., Wickerham, D. L., & Cronin, W. N. (2003). National surgical adjuvant breast and bowel project update: Prevention trials and endocrine therapy of ductal carcinoma in situ. *CLINICAL CANCER RESEARCH*, 9(1), 495S-501S. Retrieved from <http://gateway.webofknowledge.com/>
- Vogel, V. G., Costantino, J. P., Wickerham, D. L., & Cronin, W. M. (2002). Re: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study [1]. *Journal of the National Cancer Institute*, 94(19), 1504. doi:[10.1093/jnci/94.19.1504](https://doi.org/10.1093/jnci/94.19.1504)
- Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., & Wolmark, N. (2002). The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial. *Clinical Breast Cancer*, 3(2), 153-159. doi:[10.3816/CBC.2002.n.020](https://doi.org/10.3816/CBC.2002.n.020)
- Lawrence Wickerham, D., Fisher, B., Wolmark, N., Bryant, J., Costantino, J., Bernstein, L., & Runowicz, C. D. (2002). Association of tamoxifen and uterine sarcoma [4]. *Journal of Clinical Oncology*, 20(11), 2758-2760. doi:[10.1200/JCO.2002.20.11.2758](https://doi.org/10.1200/JCO.2002.20.11.2758)
- Costantino, J. (2002). The impact of hormonal treatments on quality of life of patients with metastatic breast cancer. *Clinical Therapeutics*, 24(SUPPL. C). doi:[10.1016/S0149-2918\(02\)85159-1](https://doi.org/10.1016/S0149-2918(02)85159-1)
- Costantino, J. P. (2001). Benefit/risk assessment of SERM therapy: Clinical trial versus clinical practice settings. *Annals of the New York Academy of Sciences*, 949, 280-285.
- Dunn, B. K., Anthony, M., Sherman, S., & Costantino, J. P. (2001). Conclusions: Considerations regarding SERMs. *Annals of the New York Academy of Sciences*, 949, 352-365.
- Day, R., Ganz, P. A., & Costantino, J. P. (2001). Tamoxifen and depression: More evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) randomized study. *Journal of the National Cancer Institute*, 93(21), 1615-1623. doi:[10.1093/jnci/93.21.1615](https://doi.org/10.1093/jnci/93.21.1615)
- King, M. C., Wieand, H. S., Hale, K., Walsh, T., Owens, K. M., Lee, M. K., . . . Investigators, N. S. A. B. P. (2001). Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: A genomic resequencing study in the NSABP-P1 Breast Cancer Prevention Trial (BCPT). *AMERICAN JOURNAL OF HUMAN GENETICS*, 69(4), 272. Retrieved from <http://gateway.webofknowledge.com/>
- Costantino, J. P., & Vogel, V. G. (2001). Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: An alternative view. *Clinical Breast Cancer*, 2(1), 41-46. doi:[10.3816/CBC.2001.n.009](https://doi.org/10.3816/CBC.2001.n.009)
- Gail, M. H., & Costantino, J. P. (2001). Validating and improving models for projecting the absolute risk of breast cancer. *Journal of the National Cancer Institute*, 93(5), 334-335. doi:[10.1093/jnci/93.5.334](https://doi.org/10.1093/jnci/93.5.334)
- Cushman, M., Costantino, J. P., Tracy, R. P., Song, K., Buckley, L., Roberts, J. D., & Krag, D. N. (2001). Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 21(2), 255-261. doi:[10.1161/01.ATV.21.2.255](https://doi.org/10.1161/01.ATV.21.2.255)
- Reis, S. E., Costantino, J. P., Wickerham, D. L., Tan-Chiu, E., Wang, J., & Kavanah, M. (2001). Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. *J Natl Cancer Inst*, 93(1), 16-21. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/11136837>
- Reis, S. E., Costantino, J. P., Wickerham, D. L., Tan-Chiu, E., Wang, J., & Kavanah, M. (2001). Cardiovascular effects of tamoxifen in women with and without heart disease: Breast cancer prevention trial. *Journal of the National Cancer Institute*, 93(1), 16-21. doi:[10.1093/jnci/93.1.16](https://doi.org/10.1093/jnci/93.1.16)

- Phillips, M. L., Esmen, N. A., & Costantino, J. (2001). The reliability of multiple regression and an alternative method for extracting task-specific exposure estimates from time-weighted average data. *Applied Occupational and Environmental Hygiene*, 16(1), 56-65. doi:[10.1080/104732201456131](https://doi.org/10.1080/104732201456131)
- Costantino, J. P., Vogel, V. G., & Wickerham, D. L. (2001). Reducing the risk of breast cancer: Balancing the risk-benefit analogies. *Prev Care Cancer*, 21(9), 13-21.
- King, M. C., Wieand, S., Hale, K., Lee, M., Walsh, T., Owens, K., . . . Fisher, B. (2001). Tamoxifen and breast cancer incidence among women with inherited mutations in *brca1* and *brca2* national surgical adjuvant breast and bowel project (nsabp-p1) breast cancer prevention trial. *Journal of the American Medical Association*, 286(18), 2251-2256. doi:[10.1001/jama.286.18.2251](https://doi.org/10.1001/jama.286.18.2251)
- Zborowski, J. V., Cauley, J. A., Talbott, E. O., Guzick, D. S., Vogt, M. T., & Costantino, J. P. (2000). Evidence for an interaction of polycystic ovary syndrome (PCOS) and body mass index (BMI) on bone mineral density (BMD) at the lumbar spine. *JOURNAL OF BONE AND MINERAL RESEARCH*, 15, S410. Retrieved from <http://gateway.webofknowledge.com/>
- Gail, M. H., Costantino, J. P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., & Vogel, V. (2000). RESPONSE: re: weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. *J Natl Cancer Inst*, 92(9), 758. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10793119>
- Gail, M. H., Costantino, J. P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., & Vogel, V. (2000). Re: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer - Response. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*, 92(9), 758. doi:[10.1093/jnci/92.9.758](https://doi.org/10.1093/jnci/92.9.758)
- Martin, T. J., Hovis, J. D., Costantino, J. P., Bierman, M. I., Donahoe, M. P., Rogers, R. M., . . . Sanders, M. H. (2000). A randomized, prospective evaluation of noninvasive ventilation for acute respiratory failure. *American Journal of Respiratory and Critical Care Medicine*, 161(3 I), 807-813. doi:[10.1164/ajrccm.161.3.9808143](https://doi.org/10.1164/ajrccm.161.3.9808143)
- Gail, M. H., Costantino, J. P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., & Vogel, V. (2000). Re: Risk/benefit assessment of tamoxifen to prevent breast cancer - Still a work in progress? [1] (multiple letters). *Journal of the National Cancer Institute*, 92(7), 574-575.
- Martin, T. J., Hovis, J. D., Costantino, J. P., Bierman, M. I., Donahoe, M. P., Rogers, R. M., . . . Sanders, M. H. (2000). A randomized, prospective evaluation of noninvasive ventilation for acute respiratory failure. *AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE*, 161(3), 807-813. doi:[10.1164/ajrccm.161.3.9808143](https://doi.org/10.1164/ajrccm.161.3.9808143)
- Martin, T. J., Hovis, J. D., Costantino, J. P., Bierman, M. I., Donahoe, M. P., Rogers, R. M., . . . Sanders, M. H. (2000). A randomized, prospective evaluation of noninvasive ventilation for acute respiratory failure. *Am J Respir Crit Care Med*, 161(3 Pt 1), 807-813. doi:[10.1164/ajrccm.161.3.9808143](https://doi.org/10.1164/ajrccm.161.3.9808143)
- Reis, S. E., Costantino, J. P., Wickerham, D. L., & Kavanah, M. (2000). Tamoxifen is not associated with decreased cardiac event rates in women with or without preexisting heart disease. *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*, 35(2), 301A-302A. Retrieved from <http://gateway.webofknowledge.com/>
- Sanders, M. H., Costantino, J. P., Strollo, P. J., Studnicki, K., & Atwood, C. W. (2000). The impact of split-night polysomnography for diagnosis and positive pressure therapy titration on treatment acceptance and adherence in sleep apnea/hypopnea. *Sleep*, 23(1), 17-24. doi:[10.1093/sleep/23.1.17](https://doi.org/10.1093/sleep/23.1.17)
- Fisher, B., Dignam, J., Wolmark, N., Mamounas, E., Costantino, J., Poller, W., . . . Kavanah, M. (1999). Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. *Cancer/Radiotherapy*, 3(6), 522-524.
- Cushman, M., Costantino, J. P., Bovill, E. G., Roberts, J. D., Buckley, L., Tan-Chiu, E., & Krag, D. N. (1999). Effect of tamoxifen on venous thrombosis risk factors in women without cancer: The breast cancer prevention trial (BCPT). *BLOOD*, 94(10), 239A. Retrieved from <http://gateway.webofknowledge.com/>
- Fisher, B., & Costantino, J. P. (1999). RESPONSE: re: tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. *J Natl Cancer Inst*, 91(21), 1891A-11892. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/10547399>
- Fisher, B., & Costantino, J. P. (1999). Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study - Response. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*, 91(21), 1891-1892. doi:[10.1093/jnci/91.21.1891A](https://doi.org/10.1093/jnci/91.21.1891A)

- Gail, M. H., Costantino, J. P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., & Vogel, V. (1999). Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. *Journal of the National Cancer Institute*, 91(21), 1829-1846. doi:[10.1093/jnci/91.21.1829](https://doi.org/10.1093/jnci/91.21.1829)
- Love, R. R., Fisher, B., & Costantino, J. P. (1999). Re: Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study [1] (multiple letters). *Journal of the National Cancer Institute*, 91(21), 1891-1892.
- Costantino, J. P., Gail, M. H., Pee, D., Anderson, S., Redmond, C. K., Benichou, J., & Wieand, H. S. (1999). Validation studies for models projecting the risk of invasive and total breast cancer incidence. *Journal of the National Cancer Institute*, 91(18), 1541-1548. doi:[10.1093/jnci/91.18.1541](https://doi.org/10.1093/jnci/91.18.1541)
- Day, R., Ganz, P. A., Costantino, J. P., Cronin, W. M., Wickerham, D. L., & Fisher, B. (1999). Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study. *Journal of Clinical Oncology*, 17(9), 2659-2669.
- Burshell, A. L., Anderson, S. J., Leib, E. S., Johnston, C. C., & Costantino, J. P. (1999). The effect of tamoxifen on pre and postmenopausal bone. *JOURNAL OF BONE AND MINERAL RESEARCH*, 14, S158. Retrieved from <http://gateway.webofknowledge.com/>
- Fisher, E. R., Dignam, J., Tan-Chiu, E., Costantino, J., Fisher, B., Paik, S., & Wolmark, N. (1999). Pathologic findings from the national surgical adjuvant breast project (NSABP) eight-year update of protocol b-17: Intraductal carcinoma. *Cancer*, 86(3), 429-438. doi:[10.1002/\(SICI\)1097-0142\(19990801\)86:3<429::AID-CNCR11>3.0.CO;2-Y](https://doi.org/10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y)
- Arena, V. C., Costantino, J. P., Sussman, N. B., & Redmond, C. K. (1999). Issues and findings in the evaluation of occupational risk among women high nickel alloys workers. *AMERICAN JOURNAL OF INDUSTRIAL MEDICINE*, 36(1), 114-121. doi:[10.1002/\(SICI\)1097-0274\(199907\)36:1<114::AID-AJIM16>3.0.CO;2-V](https://doi.org/10.1002/(SICI)1097-0274(199907)36:1<114::AID-AJIM16>3.0.CO;2-V)
- Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., . . . Wolmark, N. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *Journal of the National Cancer Institute*, 90(18), 1371-1388. doi:[10.1093/jnci/90.18.1371](https://doi.org/10.1093/jnci/90.18.1371)
- Smith, A. T., Kuller, L. H., Perper, J. A., Brent, D. A., Moritz, G., & Costantino, J. P. (1998). Epidemiology of homicide in Allegheny County, Pennsylvania, between 1966-1974 and 1984-1993. *Preventive Medicine*, 27(3), 452-460. doi:[10.1006/pmed.1998.0306](https://doi.org/10.1006/pmed.1998.0306)
- Gorin, M. B., Day, R., Costantino, J. P., Fisher, B., Redmond, C. K., Wickerham, L., . . . Wolmark, N. (1998). Long-term tamoxifen citrate use and potential ocular toxicity. *American Journal of Ophthalmology*, 125(4), 493-501. doi:[10.1016/S0002-9394\(99\)80190-1](https://doi.org/10.1016/S0002-9394(99)80190-1)
- Ganz, P. A., Day, R., & Costantino, J. (1998). Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. *Statistics in Medicine*, 17(5-7), 613-622.
- Fisher, B., Dignam, J., Wolmark, N., Mamounas, E., Costantino, J., Poller, W., . . . Kavanah, M. (1998). Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B- 17. *Journal of Clinical Oncology*, 16(2), 441-452. doi:[10.1200/JCO.1998.16.2.441](https://doi.org/10.1200/JCO.1998.16.2.441)
- Arena, V. C., Sussman, N. B., Redmond, C. K., Costantino, J. P., & Trauth, J. M. (1998). Using alternative comparison populations to assess occupation-related mortality risk. Results for the high nickel alloys workers cohort. *Journal of Occupational and Environmental Medicine*, 40(10), 907-916. doi:[10.1097/00043764-199810000-00012](https://doi.org/10.1097/00043764-199810000-00012)
- Bryant, J., Fisher, B., Gündüz, N., Costantino, J. P., & Emir, B. (1998). S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. *Breast Cancer Research and Treatment*, 51(3), 239-253. doi:[10.1023/A:1006184428857](https://doi.org/10.1023/A:1006184428857)
- Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Nomura, Y., . . . Schumacher, M. (1998). Tamoxifen for early breast cancer: An overview of the randomised trials. *Lancet*, 351(9114), 1451-1467. doi:[10.1016/S0140-6736\(97\)11423-4](https://doi.org/10.1016/S0140-6736(97)11423-4)
- Massoudi, M. S., Meilahn, E. N., Orchard, T. J., Foley, T. P., Kuller, L. H., Costantino, J. P., & Buhari, A. M. (1997). Thyroid function and perimenopausal lipid and weight changes: The thyroid study in healthy

- women (TSH-W). *Journal of Women's Health*, 6(5), 553-558.
- Massoudi, M. S., Meilahn, E. N., Orchard, T. J., Foley, T. P., Kuller, L. H., Costantino, J. P., & Buhari, A. M. (1997). Thyroid function and perimenopausal lipid and weight changes: The thyroid study in healthy women (TSH-W). *Journal of Women's Health*, 6(5), 553-558. doi:[10.1089/jwh.1997.6.553](https://doi.org/10.1089/jwh.1997.6.553)
- Dignam, J. J., Redmond, C. K., Fisher, B., Costantino, J. P., & Edwards, B. K. (1997). Prognosis among African-American women and white women with lymph node negative breast carcinoma - Findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). *CANCER*, 80(1), 80-90. doi:[10.1002/\(SICI\)1097-0142\(19970701\)80:1<80::AID-CNCR11>3.0.CO;2-B](https://doi.org/10.1002/(SICI)1097-0142(19970701)80:1<80::AID-CNCR11>3.0.CO;2-B)
- Costantino, J. P., Kuller, L. H., Ives, D. G., Fisher, B., & Dignam, J. (1997). Coronary heart disease mortality and adjuvant tamoxifen therapy. *Journal of the National Cancer Institute*, 89(11), 776-782. doi:[10.1093/jnci/89.11.776](https://doi.org/10.1093/jnci/89.11.776)
- Dignam, J. J., Redmond, C. K., Fisher, B., Costantino, J. P., & Edwards, B. K. (1997). Prognosis among African-American women and white women with lymph node negative breast carcinoma: Findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). *Cancer*, 80(1), 80-90. doi:[10.1002/\(SICI\)1097-0142\(19970701\)80:1<80::AID-CNCR11>3.0.CO;2-B](https://doi.org/10.1002/(SICI)1097-0142(19970701)80:1<80::AID-CNCR11>3.0.CO;2-B)
- Fisher, B., & Costantino, J. (1997). Highlights of the NSABP Breast Cancer Prevention Trial. *Cancer Control*, 4(1), 78-86. doi:[10.1177/107327489700400111](https://doi.org/10.1177/107327489700400111)
- Strollo, P. J., Sanders, M. H., Costantino, J. P., Walsh, S. K., Stiller, R. A., & Atwood, C. W. (1996). Split-night studies for the diagnosis and treatment of sleep-disordered breathing. *Sleep*, 19(10 Suppl), S255-S259. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/9085525>
- Strollo, P. J., Sanders, M. H., Costantino, J. P., Walsh, S. K., Stiller, R. A., & Atwood, C. W. (1996). Split-night studies for the diagnosis and treatment of sleep-disordered breathing. *SLEEP*, 19(10), S255-S259. doi:[10.1093/sleep/19.suppl_10.S255](https://doi.org/10.1093/sleep/19.suppl_10.S255)
- Redmond, C. K., Costantino, J. P., Anderson, S., & Yu, K. (1996). Statistical concepts and biomedical research. *Urologic Oncology*, 2(6), 166-170. doi:[10.1016/S1078-1439\(97\)00012-4](https://doi.org/10.1016/S1078-1439(97)00012-4)
- Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., . . . Lickley, H. L. (1996). Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. *Journal of the National Cancer Institute*, 88(21), 1529-1542. doi:[10.1093/jnci/88.21.1529](https://doi.org/10.1093/jnci/88.21.1529)
- Lazebnik, N., Hill, L. M., Costantino, J. P., Many, A., & Martin, J. G. (1996). Vibroacoustic stimulation enhances visualization of the four-chamber cardiac view in the third trimester. *Ultrasound in Obstetrics and Gynecology*, 8(5), 309-313. doi:[10.1046/j.1469-0705.1996.08050309.x](https://doi.org/10.1046/j.1469-0705.1996.08050309.x)
- Fisher, E. R., Costantino, J., Fisher, B., Palekar, A. S., Paik, S. M., Suarez, C. M., & Wolmark, N. (1996). Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: Five-year observations concerning lobular carcinoma in situ. *Cancer*, 78(7), 1403-1416. doi:[10.1002/\(SICI\)1097-0142\(19961001\)78:7<1403::AID-CNCR6>3.0.CO;2-L](https://doi.org/10.1002/(SICI)1097-0142(19961001)78:7<1403::AID-CNCR6>3.0.CO;2-L)
- Fisher, B., Dignam, J., Mamounas, E. P., Costantino, J. P., Wickerham, D. L., Redmond, C., . . . Margolese, R. G. (1996). Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors. *Journal of Clinical Oncology*, 14(7), 1982-1992. doi:[10.1200/JCO.1996.14.7.1982](https://doi.org/10.1200/JCO.1996.14.7.1982)
- Fisher, B., Dignam, J., Mamounas, E. P., Costantino, J. P., Wickerham, D. L., Redmond, C., . . . Margolese, R. G. (1996). Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: Eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. *JOURNAL OF CLINICAL ONCOLOGY*, 14(7), 1982-1992. doi:[10.1200/JCO.1996.14.7.1982](https://doi.org/10.1200/JCO.1996.14.7.1982)
- Redmond, C. K., & Costantino, J. P. (1996). Design and current status of the NSABP breast cancer prevention trial. *Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer*, 140, 309-317.
- Antoniades, K., Fisher, E. R., Costantino, J., Palekar, A. S., Mamounas, E., & Fisher, B. (1995). Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B-17: Intraductal carcinoma (ductal carcinoma in situ). *Cancer*, 76(11), 2385-2387. doi:[10.1002/1097-0142\(19951201\)76:11<2385::AID-CNCR2820761132>3.0.CO;2-V](https://doi.org/10.1002/1097-0142(19951201)76:11<2385::AID-CNCR2820761132>3.0.CO;2-V)

- ANDERSON, S. J., COSTANTINO, J. P., BROWN, A. M., BRYANT, J. L., CRONIN, W. M., DIGNAM, J. J., . . . WIEAND, S. (1995). BREAST-CANCER TRIALS ON TRIAL - A CASE OF CONFLICTING ETHICAL INTERESTS. *CANCER*, 76(7), 1294-1295. doi:[10.1002/1097-0142\(19951001\)76:7<1294::AID-CNCR2820760729>3.0.CO;2-U](https://doi.org/10.1002/1097-0142(19951001)76:7<1294::AID-CNCR2820760729>3.0.CO;2-U)
- Anderson, S. J., Costantino, J. P., Brown, A. M., Bryant, J. L., Cronin, W. M., Dignam, J. J., . . . Wieand, S. (1995). Breast cancer trials on trial: A case of conflicting ethical interests. *Cancer*, 76(7), 1294-1295. doi:[10.1002/1097-0142\(19951001\)76:7<1294::AID-CNCR2820760729>3.0.CO;2-U](https://doi.org/10.1002/1097-0142(19951001)76:7<1294::AID-CNCR2820760729>3.0.CO;2-U)
- Massoudi, M. S., Meilahn, E. N., Orchard, T. J., Foley, T. P., Kuller, L. H., Costantino, J. P., & Buhari, A. M. (1995). Prevalence of thyroid antibodies among healthy middle-aged women. Findings from the thyroid study in healthy women. *Ann Epidemiol*, 5(3), 229-233. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/7606312>
- Costantino, J. P., Redmond, C. K., & Bearden, A. (1995). Occupationally related cancer risk among coke oven workers: 30 years of follow-up. *Journal of Occupational and Environmental Medicine*, 37(5), 597-604. doi:[10.1097/00043764-199505000-00009](https://doi.org/10.1097/00043764-199505000-00009)
- Massoudi, M. S., Meilahn, E. N., Orchard, T. J., Foley, T. P., Kuller, L. H., Costantino, J. P., & Buhari, A. M. (1995). Prevalence of thyroid antibodies among healthy middle-aged women. Findings from the thyroid study in healthy women. *Annals of Epidemiology*, 5(3), 229-233. doi:[10.1016/1047-2797\(94\)00110-F](https://doi.org/10.1016/1047-2797(94)00110-F)
- Fisher, E. R., Costantino, J., Fisher, B., Palekar, A. S., & Redmond, C. (1995). Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). *Cancer*, 75(6), 1310-1319. doi:[10.1002/1097-0142\(19950315\)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G](https://doi.org/10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G)
- Fisher, E. R., Costantino, J., Fisher, B., Palekar, A. S., Redmond, C., & Mamounas, E. (1995). Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. *Cancer*, 75(6), 1310-1319. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/7882281>
- Fisher, E. R., Costantino, J. P., Fisher, B., Palekar, A. S., & Mamounas, E. (1995). Blunting the counterpoint. *Cancer*, 75, 1224-1227.
- Fisher, E. R., Palekar, A. S., Costantino, J., Fisher, B., & Mamounas, E. (1995). Response—blunting the counterpoint. *Cancer*, 75(6), 1223-1227. doi:[10.1002/1097-0142\(19950315\)75:6<1223::AID-CNCR2820750603>3.0.CO;2-A](https://doi.org/10.1002/1097-0142(19950315)75:6<1223::AID-CNCR2820750603>3.0.CO;2-A)
- Fisher, E. R., Costantino, J. P., & Fisher, B. (1994). Response to arnold. *Journal of the National Cancer Institute*, 86(24), 1878-1879. doi:[10.1093/jnci/86.24.1878](https://doi.org/10.1093/jnci/86.24.1878)
- FISHER, E. R., FISHER, B., WICKERHAM, D. L., COSTANTINO, J. P., & REDMOND, C. (1994). ENDOMETRIAL CANCER IN TAMOXIFEN-TREATED BREAST-CANCER PATIENTS - FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP)-B-14 - REPLY. *JOURNAL OF THE NATIONAL CANCER INSTITUTE*, 86(16), 1255. Retrieved from <http://gateway.webofknowledge.com/>
- Fisher, E. R., Fisher, B., Wickerham, D. L., Costantino, J. P., & Redmond, C. (1994). Responses. *Journal of the National Cancer Institute*, 86(16), 1253-1254. doi:[10.1093/jnci/86.16.1253](https://doi.org/10.1093/jnci/86.16.1253)
- Fisher, E. R., Fisher, B., Wickerham, D. L., Costantino, J. P., & Redmond, C. (1994). Correspondence. *Journal of the National Cancer Institute*, 86(16), 1254-1255. doi:[10.1093/jnci/86.16.1254](https://doi.org/10.1093/jnci/86.16.1254)
- Sanders, M. H., Kern, N. B., Costantino, J. P., Stiller, R. A., Strollo, P. J., Studnicki, K. A., . . . Richards, T. J. (1994). Accuracy of end-tidal and transcutaneous PCO₂ monitoring during sleep. *Chest*, 106(2), 472-483. doi:[10.1378/chest.106.2.472](https://doi.org/10.1378/chest.106.2.472)
- Costantino, J. P., Redmond, C. K., & Fisher, B. (1994). Response. *Journal of the National Cancer Institute*, 86(13), 1025-1026. doi:[10.1093/jnci/86.13.1025-a](https://doi.org/10.1093/jnci/86.13.1025-a)
- Costantino, J. P. (1994). Stat bite: Breast cancer risk in prevention trial participants. *Journal of the National Cancer Institute*, 86(13), 959. doi:[10.1093/jnci/86.13.959](https://doi.org/10.1093/jnci/86.13.959)
- Fisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., & Cronin, W. M. (1994). Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the national surgical adjuvant breast and bowel project (NSABP) B-14. *Journal of the National Cancer Institute*, 86(7), 527-537. doi:[10.1093/jnci/86.7.527](https://doi.org/10.1093/jnci/86.7.527)

- Slesinski, M. J., Gloninger, M. F., Costantino, J. P., & Orenstein, D. M. (1994). Lipid levels in adults with cystic fibrosis. *Journal of the American Dietetic Association*, 94(4), 402-408. doi:[10.1016/0002-8223\(94\)90095-7](https://doi.org/10.1016/0002-8223(94)90095-7)
- Fisher, E. R., & Costantino, J. (1994). Quality assurance of pathology in clinical trials. The National Surgical Adjuvant Breast and Bowel Project experience. *Cancer*, 74(9 Suppl), 2638-2641. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/7954278>
- Fisher, E. R., Palekar, A. S., Stoner, F., & Costantino, J. P. (1994). Mucocele-like lesions and mucinous carcinoma of breast. *Internat J Surg Path*, 4(0), 213-220.
- Fisher, E. R., Palekar, A. S., Stoner, F., & Costantino, J. (1994). Mucocele-like Lesions and Mucinous Carcinoma of the Breast. *International Journal of Surgical Pathology*, 1(4), 213-220. doi:[10.1177/106689699400100401](https://doi.org/10.1177/106689699400100401)
- Fisher, E. R., & Costantino, J. (1994). Quality assurance of pathology in clinical trials: The national surgical adjuvant breast and bowel project experience. *Cancer*, 74(9 S), 2638-2641. doi:[10.1002/1097-0142\(19941101\)74:9+<2638::AID-CNCR2820741809>3.0.CO;2-8](https://doi.org/10.1002/1097-0142(19941101)74:9+<2638::AID-CNCR2820741809>3.0.CO;2-8)
- Sanders, M. H., Kern, N. B., Costantino, J. P., Stiller, R. A., Studnicki, K., Coates, J., . . . Schirmerman, S. (1993). Prescription of positive airway pressure for sleep apnea on the basis of a partial-night trial. *Sleep*, 16(8 Suppl), S106-S107. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8177993>
- SANDERS, M. H., KERN, N. B., COSTANTINO, J. P., STILLER, R. A., STUDNICKI, K., COATES, J., . . . SCHIRMERMAN, S. (1993). PRESCRIPTION OF POSITIVE AIRWAY PRESSURE FOR SLEEP-APNEA ON THE BASIS OF A PARTIAL-NIGHT TRIAL. *SLEEP*, 16(8), S106-S107. doi:[10.1093/sleep/16.suppl.8.S106](https://doi.org/10.1093/sleep/16.suppl.8.S106)
- Fisher, B., Costantino, J., Redmond, C., Fisher, E., Margolese, R., Dimitrov, N., . . . Kavanah, M. (1993). Lumpectomy Compared with Lumpectomy and Radiation Therapy for the Treatment of Intraductal Breast Cancer. *New England Journal of Medicine*, 328(22), 1581-1586. doi:[10.1056/NEJM199306033282201](https://doi.org/10.1056/NEJM199306033282201)
- Sanders, M. H., Kern, N. B., Costantino, J. P., Stiller, R. A., Studnicki, K., Coates, J., . . . Schirmerman, S. (1993). Adequacy of prescribing positive airway pressure therapy by mask for sleep apnea on the basis of a partial-night trial. *American Review of Respiratory Disease*, 147(5), 1169-1174. doi:[10.1164/ajrccm/147.5.1169](https://doi.org/10.1164/ajrccm/147.5.1169)
- Fisher, E. R., Costantino, J., Fisher, B., & Redmond, C. (1993). Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators. *Cancer*, 71(6 Suppl), 2141-2150. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/8443763>
- Rogers, R. M., Donahoe, M., & Costantino, J. (1992). Physiologic effects of oral supplemental feeding in malnourished patients with chronic obstructive pulmonary disease: A randomized control study. *American Review of Respiratory Disease*, 146(6), 1511-1517. doi:[10.1164/ajrccm/146.6.1511](https://doi.org/10.1164/ajrccm/146.6.1511)
- Sanders, M. H., Black, J., Costantino, J. P., Kern, N., Studnicki, K., & Coates, J. (1991). Diagnosis of sleep-disordered breathing by half-night polysomnography. *American Review of Respiratory Disease*, 144(6), 1256-1261. doi:[10.1164/ajrccm/144.6.1256](https://doi.org/10.1164/ajrccm/144.6.1256)
- Fisher, B., Gunduz, N., Costantino, J., Fisher, E. R., Redmond, C., Mamounas, E. P., & Siderits, R. (1991). DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S-Phase fraction to outcome of patients in NSABP B-04. *Cancer*, 68(7), 1465-1475. doi:[10.1002/1097-0142\(19911001\)68:7<1465::AID-CNCR2820680702>3.0.CO;2-I](https://doi.org/10.1002/1097-0142(19911001)68:7<1465::AID-CNCR2820680702>3.0.CO;2-I)
- Sciurba, F. C., Owens, G. R., Sanders, M. H., Costantino, J. P., Paradis, I. L., & Griffith, B. P. (1991). The effect of obliterative bronchiolitis on breathing pattern during exercise in recipients of heart-lung transplants. *American Review of Respiratory Disease*, 144(1), 131-135. doi:[10.1164/ajrccm/144.1.131](https://doi.org/10.1164/ajrccm/144.1.131)
- Zhou, S. Y. J., Mazumdar, S., Redmond, C. K., Dong, M. H., & Costantino, J. P. (1991). Computations of adjusted rates and lifetime risks from occupational cohort data: A program package using FORTRAN and GLIM. *Computers and Biomedical Research*, 24(1), 29-46. doi:[10.1016/0010-4809\(91\)90011-K](https://doi.org/10.1016/0010-4809(91)90011-K)
- Mazumdar, S., Redmond, C. K., Costantino, J. P., Patwardhan, R. N., & Zhou, S. Y. J. (1991). Recent developments in the multistage modeling of cohort data for carcinogenic risk assessment. *Environmental Health Perspectives*, 90, 271-277. doi:[10.2307/3430878](https://doi.org/10.2307/3430878)

- Pollak, M., Costantino, J., Polychronakos, C., Blauer, S. A., Guyda, H., Redmond, C., . . . Margolese, R. (1990). Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. *Journal of the National Cancer Institute*, 82(21), 1693-1697. doi:[10.1093/jnci/82.21.1693](https://doi.org/10.1093/jnci/82.21.1693)
- Steen, V. D., Costantino, J. P., Shapiro, A. P., & Medsger, T. A. (1990). Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors. *Annals of Internal Medicine*, 113(5), 352-357. doi:[10.7326/0003-4819-113-5-352](https://doi.org/10.7326/0003-4819-113-5-352)
- Werchowski, J. L., Sanders, M. H., Costantino, J. P., Scirba, F. C., & Rogers, R. M. (1990). Inductance plethysmograph measurement of CPAP-induced changes in end-expiratory lung volume. *Journal of Applied Physiology*, 68(4), 1732-1738.
- Sanders, M. H., Costantino, J. P., & Johnson, J. T. (1990). Polysomnography early after uvulopalatopharyngoplasty as a predictor of late postoperative results. *Chest*, 97(4), 913-919. doi:[10.1378/chest.97.4.913](https://doi.org/10.1378/chest.97.4.913)
- Mazumdar, S., Redmond, C. K., Enterline, P. E., Marsh, G. M., Costantino, J. P., Zhou, S. Y. J., & Patwardhan, R. N. (1989). Multistage Modeling of Lung Cancer Mortality Among Arsenic-Exposed Copper-Smelter Workers. *Risk Analysis*, 9(4), 551-563. doi:[10.1111/j.1539-6924.1989.tb01266.x](https://doi.org/10.1111/j.1539-6924.1989.tb01266.x)
- Sanders, M. H., Constantino, J. P., Owens, G. R., Scirba, F. C., Rogers, R. M., Reynolds, C. F., . . . Hardesty, R. L. (1989). Breathing during wakefulness and sleep after human heart-lung transplantation. *American Review of Respiratory Disease*, 140(1), 45-51. doi:[10.1164/ajrccm/140.1.45](https://doi.org/10.1164/ajrccm/140.1.45)
- Redmond, C., Fisher, C. K., Costantino, B., Wickerham, J., Wolmark, D. L., & Fisher, N. (1989). Treatment of stage I breast cancer: The NSABP experience. *Hormone Research in Paediatrics*, 32, 175-180. doi:[10.1159/000181340](https://doi.org/10.1159/000181340)
- Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., . . . Ketner, M. (1989). A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor-Positive Tumors. *New England Journal of Medicine*, 320(8), 479-484. doi:[10.1056/NEJM198902233200802](https://doi.org/10.1056/NEJM198902233200802)
- Mazumdar, S., Redmond, C. K., Enterline, P. E., Marsh, G. M., Costantino, J. P., Zhou, S. Y., & Patwardhan, R. N. (1989). Multistage modeling of lung cancer mortality among arsenic-exposed copper-smelter workers.. *Risk Anal*, 9(4), 551-563. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/2608948>
- Scirba, F. C., Owens, G. R., Sanders, M. H., Griffith, B. P., Hardesty, R. L., Paradis, I. L., & Costantino, J. P. (1988). Evidence of an Altered Pattern of Breathing during Exercise in Recipients of Heart-Lung Transplants. *New England Journal of Medicine*, 319(18), 1186-1192. doi:[10.1056/NEJM198811033191803](https://doi.org/10.1056/NEJM198811033191803)
- Costantino, J. P., Kuller, L. H., Begg, L., Redmond, C. K., & Bates, M. W. (1988). Serum level changes after administration of a pharmacologic dose of β -carotene. *American Journal of Clinical Nutrition*, 48(5), 1277-1283. doi:[10.1093/ajcn/48.5.1277](https://doi.org/10.1093/ajcn/48.5.1277)
- Dong, M. H., Redmond, C. K., Mazumdar, S., & Costantino, J. P. (1988). A multistage approach to the cohort analysis of lifetime lung cancer risk among steelworkers exposed to coke oven emissions. *American Journal of Epidemiology*, 128(4), 860-873. doi:[10.1093/oxfordjournals.aje.a115039](https://doi.org/10.1093/oxfordjournals.aje.a115039)
- Bender, M. A., Leonard, R. C., Otto White, J., Constantino, J. P., & Redmond, C. K. (1988). Chromosomal aberrations and sister-chromatid exchanges in lymphocytes from coke oven workers. *Mutation Research/Genetic Toxicology*, 206(1), 11-16. doi:[10.1016/0165-1218\(88\)90135-8](https://doi.org/10.1016/0165-1218(88)90135-8)
- Taylor, S. R., Blatt, J., Costantino, J. P., Roederer, M., & Murphy, R. F. (1988). Flow cytometric DNA analysis of Neuroblastoma and Ganglioneuroma. A 10-year retrospective study. *Cancer*, 62(4), 749-754. doi:[10.1002/1097-0142\(19880815\)62:4<749::AID-CNCR2820620418>3.0.CO;2-W](https://doi.org/10.1002/1097-0142(19880815)62:4<749::AID-CNCR2820620418>3.0.CO;2-W)
- Marsh, G. M., Costantino, J. P., & Lyons, E. (1988). Health effects of exposure to Drake Chemical Company superfund site; Mortality among former employees and family members.. *J Environ Hlth*, 50(7), 389-394.
- MAZUMDAR, S., REDMOND, C. K., COSTANTINO, J. P., MARSH, G. M., CHOU, S., & NALAVADE, R. (1988). MULTISTAGE MODELING OF EPIDEMIOLOGIC DATA - A GENERALIZED COMPUTER-PROGRAM FOR QUANTITATIVE RISK ASSESSMENT. *ARCHIVES OF ENVIRONMENTAL HEALTH*, 43(2), 203. Retrieved from <http://gateway.webofknowledge.com/>
- Marsh, G. M., Costantino, J. P., Logue, J. N., Fox, J. M., & Lyons, E. E. (1988). Exposure to the drake superfund site: morbidity among former employees and family members. *Journal of Environmental Health*, 50(7),

389-394.

- Costantino, J. P., Richter, H. W., Lee Go, C. H., & Waddell, W. H. (1985). Kinetic Analysis of the Photoinitiated Autocatalytic Chain Decomposition of Phenyl Azide. A Molecular Explosion in Solution. *Journal of the American Chemical Society*, 107(6), 1744-1747. doi:[10.1021/ja00292a048](https://doi.org/10.1021/ja00292a048)
- Costantino, J. P. (1981). HEALTH EFFECTS OF RESPIRABLE COAL MINE DUST: COAL WORKERS' PNEUMOCONIOSIS.. *Progress in Nuclear Energy*.
- Glickman, L. T., Chaudry, I. U., Costantino, J., Clack, F. B., Cypess, R. H., & Winslow, L. (1981). Pica patterns, toxocariasis, and elevated blood lead in children.. *Am J Trop Med Hyg*, 30(1), 77-80. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/7212174>
- Costantino, J. P. (1981). HEALTH EFFECTS OF RESPIRABLE COAL MINE DUST: COAL WORKERS' PNEUMOCONIOSIS.. *Progress in Nuclear Energy*.
- Costantino, J. P. (1980). 'Health costs of air pollution' challenged.. *American Journal of Public Health*, 70(7), 744.
- Costantino, J. P. (1978). The author replies. *American Journal of Epidemiology*, 108(2), 158-159. doi:[10.1093/oxfordjournals.aje.a112602](https://doi.org/10.1093/oxfordjournals.aje.a112602)
- COSTANTINO, J. P. (1978). AN EPIDEMIOLOGIC-STUDY OF HOMICIDES IN ALLEGHENY COUNTY, PENNSYLVANIA - REPLY. *AMERICAN JOURNAL OF EPIDEMIOLOGY*, 108(2), 158-159. doi:[10.1093/oxfordjournals.aje.a112602](https://doi.org/10.1093/oxfordjournals.aje.a112602)
- Costantino, J. P., Kuller, L. H., Perper, J. A., & Cypess, R. H. (1977). An epidemiologic study of homicides in allegheny county, pennsylvania. *American Journal of Epidemiology*, 106(4), 314-324. doi:[10.1093/oxfordjournals.aje.a112467](https://doi.org/10.1093/oxfordjournals.aje.a112467)
- COSTANTINO, J. P., KULLER, L., PERPER, J., & CYPESS, R. (1976). EPIDEMIOLOGIC-STUDY OF HOMICIDES IN ALLEGHENY COUNTY, PENNSYLVANIA. *AMERICAN JOURNAL OF EPIDEMIOLOGY*, 104(3), 324. Retrieved from <http://gateway.webofknowledge.com/>
- Ingle, J., Wickerham, D. L., Kalari, K. R., Goetz, M. P., Barman, P., Carlson, E. E., . . . Weinshilboum, R. M. (n.d.). Genome-wide association (GWAS) study in women receiving neoadjuvant chemotherapy with or without bevacizumab on NSABP B-40.. *Cancer Discovery*.

Presentations

- Vicini, F. A., Cecchini, R. S., White, J. R., Julian, T. B., Arthur, D. W., Rabinovitch, R. A., . . . Wolmark, N. (2018). Primary Results of NSABP B-39 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer.. In *2018 San Antonio Breast Cancer Symposium*. San Antonio, TX.
- Kim, R., Song, N., Gavin, P., Salgado, R., Bandos, H., Kos, Z., . . . Wolmark, N. (2018). NRG Oncology/NSABP B-31: Stromal tumor infiltrating lymphocytes (sTILs) and outcomes in early-stage HER2-positive breast cancer (BC).. In *American Society of Clinical Oncology*. Chicago, IL.
- Ferenbacher, L., Cecchini, R. S., Geyer, C. E., Rastogi, P., Costantino, J. P., Atkins, J. N., . . . Wolmark, N. (2017). NSABP B-47 (NRG Oncology): Phase III randomized trial comparing adjuvant chemotherapy with Adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC). In *Society for Clinical Oncology Annual Meeting 2017*. Chicago, IL.
- Robidoux, A., Tang, G., Rastogi, P., Geyer, C. E., Azar, C. A., Atkins, J. N., . . . Wolmark, N. (2016). Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+operable breast cancer: 5-year outcomes of NSABP protocol B-41.. doi:[10.1200/JCO.2016.34.15_suppl.501](https://doi.org/10.1200/JCO.2016.34.15_suppl.501)
- Ganz, P. A., Cecchini, R. S., Julian, T. B., Margolese, R. G., Costantino, J. P., Vallow, L. A., . . . Wolmark, N. (2016). Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. doi:[10.1158/1538-7445.SABCS15-S6-04](https://doi.org/10.1158/1538-7445.SABCS15-S6-04)
- Wickerham, D. L., Cecchini, R. S., Vogel, V. G., Costantino, J. P., Cronin, W. M., Bevers, T. B., . . . Wolmark, N. (2015). Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer. doi:[10.1200/jco.2015.33.15_suppl.1500](https://doi.org/10.1200/jco.2015.33.15_suppl.1500)
- Walcott, F. L., Land, S. R., Costantino, J. P., Midthune, D., & Dunn, B. K. (2015). Vasomotor symptoms, BMI,

- and adherence to tamoxifen in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (P-1). doi:[10.1200/jco.2015.33.15_suppl.1501](https://doi.org/10.1200/jco.2015.33.15_suppl.1501)
- Kim, S. -R., Gavin, P. G., Pogue-Geile, K. L., Song, N., Finnigan, M., Bandos, H., . . . Wolmark, N. (2015). A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+breast cancer. doi:[10.1158/1538-7445.AM2015-2837](https://doi.org/10.1158/1538-7445.AM2015-2837)
- O'Sullivan, C. C., Holmes, E., Spielmann, M., Perez, E. A., Joensuu, H., Costantino, J. P., . . . Gelber, R. D. (2013). The prognosis of small HER2+breast cancers: A meta-analysis of the randomized trastuzumab trials. doi:[10.1158/0008-5472.SABCS13-S6-03](https://doi.org/10.1158/0008-5472.SABCS13-S6-03)
- Cecchini, R. S., Swain, S. M., Costantino, J. P., Rastogi, P., Jeong, J. -H., Anderson, S. J., . . . Wolmark, N. (2013). Body mass index at diagnosis and breast cancer survival prognosis among clinical trial populations: Results from NSABP B-30, B-31, B-34, and B-38. doi:[10.1158/0008-5472.SABCS13-PD2-1](https://doi.org/10.1158/0008-5472.SABCS13-PD2-1)
- Slamon, D. J., Swain, S. M., Buyse, M., Martin, M., Geyer, C. E., Im, Y. -H., . . . Wolmark, N. (2013). Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab +/- bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. doi:[10.1158/0008-5472.SABCS13-S1-03](https://doi.org/10.1158/0008-5472.SABCS13-S1-03)
- Julian, T. B., Anderson, S. J., Krag, D. N., Weaver, D. L., Costantino, J. P., Ashikaga, T., . . . Wolmark, N. (2013). 10-yr follow-up results of occult detected sentinel node disease: NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. doi:[10.1158/0008-5472.SABCS13-S2-05](https://doi.org/10.1158/0008-5472.SABCS13-S2-05)
- Mamounas, E. P., Tang, G., Paik, S., Baehner, F. L., Liu, Q., Jeong, J., . . . Wolmark, N. (2013). The 21-gene Recurrence Score (RS) Predicts Risk of Loco-regional Recurrence (LRR) in Node (+), ER (+) Breast Cancer (BC) after Adjuvant Chemotherapy and Tamoxifen: Results from NSABP B-28. Retrieved from <http://gateway.webofknowledge.com/>
- Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J., Wolmark, N., . . . von Minckwitz, G. (2012). Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). doi:[10.1158/0008-5472.SABCS12-S1-11](https://doi.org/10.1158/0008-5472.SABCS12-S1-11)
- Mamounas, E. P., Tang, G., Paik, S., Baehner, F. L., Liu, Q., Jeong, J. -H., . . . Wolmark, N. (2012). Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N plus), ER-positive breast cancer patients (pts): Results from NSABP B-28. doi:[10.1158/0008-5472.SABCS12-S1-10](https://doi.org/10.1158/0008-5472.SABCS12-S1-10)
- Costantino, J. P. (2012, November 10). The Risk prediction, benefit/risk assessment and risk communication in breast cancer chemoprevention.. In *The National Institute of Health Biostatistics Symposium: Statistics in Biomedical Research-Making and Translating New Discoveries*. Bethesda, MD.
- Mamounas, E. P., Tang, G., Paik, S., Baehner, F. L., Liu, Q., Jeong, J. -H., . . . Wolmark, N. (2012). Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28.. Retrieved from <http://gateway.webofknowledge.com/>
- Swain, S. M., Tang, G., Geyer, C. E., Rastogi, P., Atkins, J. N., Donnellan, P. P., . . . Wolmark, N. (2012). NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. doi:[10.1200/jco.2012.30.18_suppl.lba1000](https://doi.org/10.1200/jco.2012.30.18_suppl.lba1000)
- Paterson, A. H. G., Anderson, S. J., Lembersky, B. C., Fehrenbacher, L., Falkson, C. I., King, K. M., . . . Wolmark, N. (2011). NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy Final Analysis.. doi:[10.1158/0008-5472.SABCS11-52-3](https://doi.org/10.1158/0008-5472.SABCS11-52-3)
- Julian, T. B., Costantino, J. P., Vicini, F. A., White, J. R., Winter, K. A., Arthur, D. W., . . . Wolmark, N. (2011). Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial.. Retrieved from <http://gateway.webofknowledge.com/>
- Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Robidoux, A., Atkins, J. N., . . . Wolmark, N. (2011). The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP

- protocol B-40. Retrieved from <http://gateway.webofknowledge.com/>
- Land, S. R., Christian, N., Wickerham, D. L., Costantino, J. P., & Ganz, P. A. (2011). Cigarette smoking, fitness, and alcohol use as predictors of cancer outcomes among women in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT).. doi:[10.1200/jco.2011.29.15_suppl.1505](https://doi.org/10.1200/jco.2011.29.15_suppl.1505)
- Tang, G., Costantino, J. P., Crager, M., Shak, S., & Wolmark, N. (2010). Comparing the Prediction of Chemotherapy Benefit in Patients with Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and a New Measure That Integrates Clinical and Pathologic Factors with the Recurrence Score. doi:[10.1158/0008-5472.SABCS10-S4-9](https://doi.org/10.1158/0008-5472.SABCS10-S4-9)
- Thomas, C. R., Glover, K. Z., Constantino, J. P., Feingold, E., & Wilson, J. W. (2010). Comparison of African American (AA) and White (W) Patients with Respect to Radiotherapy (RT) Delivery in National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Treatment Trials. doi:[10.1016/j.ijrobp.2010.07.066](https://doi.org/10.1016/j.ijrobp.2010.07.066)
- Julian, T. B., Costantino, J. P., Vicini, F. A., White, J. R., Winter, K. A., Anhui, D. W., . . . Wolmark, N. (2011). Early Toxicity Results with 3-D Conformal External Beam Therapy (CEBT) from the NSABP B-39/RTOG 0413 Accelerated Partial Breast Irradiation (APBI) Trial. doi:[10.1016/j.ijrobp.2011.06.014](https://doi.org/10.1016/j.ijrobp.2011.06.014)
- Krag, D. N., Anderson, S. J., Julian, T. B., Brown, A., Harlow, S. P., Costantino, J. P., . . . Wolmark, N. (2010). Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients.. Retrieved from <http://gateway.webofknowledge.com/>
- Tang, G., Cuzick, J., Wale, C., Costantino, J. P., Crager, M., Shak, S., . . . Forbes, J. F. (2010). Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach. Retrieved from <http://gateway.webofknowledge.com/>
- Yang, S. X., Costantino, J. P., Nguyen, D., Jeong, J., Mamounas, E. P., Wolmark, N., . . . Swain, S. M. (2009). Correlation of levels of Akt phosphorylation at Ser473 with benefit from paclitaxel chemotherapy in NSABP B-28 patients with node-positive breast cancer. Retrieved from <http://gateway.webofknowledge.com/>
- Ganz, P. A., Land, S. R., Geyer, C. E., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., . . . Swain, S. M. (2009). NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.. Retrieved from <http://gateway.webofknowledge.com/>
- Costantino, J. P. (2008, October 16). Breast Cancer Prevention.. In *Global Health in the 21st Century: The Latest Successful Perceptions*. Washington, DC.
- Costantino, J. P. (2008, October 14). Chemoprevention of Breast Cancer: Communicating the benefits and risks.. Memorial Sloan-Kettering Cancer Center. Seminars in Prevention, Control, and Population Research.
- Julian, T. B., Fourchette, V., Anderson, S., Mamounas, E. P., Costantino, J. P., Boudros, E., . . . Wolmark, N. (2008). Predictive factors for which a breast cancer sentinel lymph node biopsy can be avoided. Retrieved from <http://gateway.webofknowledge.com/>
- Julian, T. B., Anderson, S., Fourchette, V., Zieger, S., Mamounas, E., Bear, H., . . . Wolmark, N. (2007). Predictive factors associated with invasive lobular breast cancer after neoadjuvant chemotherapy. Retrieved from <http://gateway.webofknowledge.com/>
- Vogel, V. G., Costantino, J. P., Wickerham, D. L., & Wolmark, N. (2006). The effects of tamoxifen versus raloxifene on the risk of developing noninvasive breast cancer in the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial.. Retrieved from <http://gateway.webofknowledge.com/>
- Mamounas, E., Jeong, J. -H., Wickerham, L., Smith, R., Geyer, C., Ganz, P., . . . Wolmark, N. (2006). Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33.. Retrieved from <http://gateway.webofknowledge.com/>
- Wickerham, D. L., Costantino, J. P., Vogel, V., Cronin, W., Cecchini, R., Ford, L., & Wolmark, N. (2006). Fracture results from the study of tamoxifen and raloxifene (STAR).. Retrieved from <http://gateway.webofknowledge.com/>

- Wickerham, D. L., Costantino, J. P., Vogel, V., Cronin, W., Cecchini, R., Atkins, J., . . . Wolmark, N. (2006). The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study. Retrieved from <http://gateway.webofknowledge.com/>
- O'Connell, M. J., Paik, S., Yothers, G., Costantino, J. P., Cowens, J. W., Clark, K. M., . . . Wolmark, N. (2006). Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue.. Retrieved from <http://gateway.webofknowledge.com/>
- Julian, T. B., Anderson, S., Brown, A., Krag, D., Harlow, S., Bear, H., . . . Wolmark, N. (2005). Continued technical results of NSABP B-32: Does a positive sentinel node biopsy require an axillary dissection?. Retrieved from <http://gateway.webofknowledge.com/>
- Costantino, J. P. (2005, November 12). The Breast Cancer Risk: Accurately Relating Risk to Patients and Risk Reduction Strategies.. In *6th Annual Symposium on Advances in Comprehensive Breast Cancer*. University of Virginia School of Medicine. Charlottesville, Va..
- Wapnir, I., Anderson, S., Mamounas, E., Geyer, C., Hyeon-Jeong, J., Costantino, J., . . . Wolmark, N. (2005). Survival after IBTR in NSABP node negative protocols B-13, B-14, B-19, B-20 and B-23.. Retrieved from <http://gateway.webofknowledge.com/>
- Land, S. R., Kopec, J. A., Julian, T. B., Brown, A., Krag, D. N., Harlow, S., . . . Ganz, P. A. (2005). Comparison of self-reported outcomes with arm functional measurements in early breast cancer patients undergoing nodal biopsy in NSABP protocol B-32.. Retrieved from <http://gateway.webofknowledge.com/>
- Holmberg, C., Adams-Campbell, L., Costantino, J. P., Pearson, J., & Mccaskill-Stevens, W. (2005). Determinants of participation in the study of tamoxifen and raloxifene (STAR): Experience of a minority-based community oncology program.. Retrieved from <http://gateway.webofknowledge.com/>
- Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., . . . Wolmark, N. (2005). Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer.. Retrieved from <http://gateway.webofknowledge.com/>
- Garber, J. E., Costantino, J. P., Wickerham, D. L., Berliner, N., & Wolmark, N. (2002). Factor V Leiden (FVL) and prothrombin G20210A (PTG) mutations and risk of thromboembolic events (TE) in NSABP P-1, the breast cancer prevention trial (BCPT).. Retrieved from <http://gateway.webofknowledge.com/>
- Wang, J., Costantino, J. P., Tan-Chiu, E., Wickerham, D. L., & Wolmark, N. (2002). Benign breast disease and the risk of subsequent invasive breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project's breast cancer prevention trial.. Retrieved from <http://gateway.webofknowledge.com/>
- Tan-Chiu, E., Costantino, J., Wang, J., Paik, S., Butch, C., Wickerham, D. L., & Wolmark, N. (2001). The effect of tamoxifen on benign breast disease. Findings from the national surgical adjuvant breast and bowel project (NSABP) breast cancer prevention trial (BCPT).
- Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., & Wolmark, N. (2001). The study of Tamoxifen and Raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial. doi:[10.3816/CBC.2002.n.020](https://doi.org/10.3816/CBC.2002.n.020)
- Costantino, J. P. (2000, February 11). Evaluating women for preventative prescription: risk assessment and counseling.. In *Michigan State University, East Lansing, MI*. East Lansing, MI.
- Costantino, J. P., & Casuccio, G. S. (1984). RELATIONSHIP BETWEEN PARTICULATE MATTER COLLECTED BY COLLOCATED D//OPM//1//0 AND Hi-Vol SAMPLERS..
- Costantino, J. P., Janocko, P. B., Casuccio, G. S., & Kerch, R. L. (1983). THORACIC PARTICULATE LEVELS AT SURFACE MINING OPERATIONS DETERMINED BY AUTOMATED MICROSCOPIC ANALYSIS OF HI-VOL FILTERS..
- Costantino, J. P. (1981). Health effects of respirable coal mine dust: Coal workers' pneumoconiosis.
- Robidoux, A., Tang, G., Rastogi, P., Geyer, C. E., Azar, C. A., Atkins, J. N., . . . Wolmark, N. (2012). Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+operable breast cancer: NSABP protocol B-41. doi:[10.1200/jco.2012.30.18_suppl.lba506](https://doi.org/10.1200/jco.2012.30.18_suppl.lba506)
- Swain, S. M., Jeong, J. -H., Geyer, C. E., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., . . . Wolmark, N. (2009).

NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.. Retrieved from <http://gateway.webofknowledge.com/>